[go: up one dir, main page]

US20060011666A1 - Pipette/applicator - Google Patents

Pipette/applicator Download PDF

Info

Publication number
US20060011666A1
US20060011666A1 US10/892,261 US89226104A US2006011666A1 US 20060011666 A1 US20060011666 A1 US 20060011666A1 US 89226104 A US89226104 A US 89226104A US 2006011666 A1 US2006011666 A1 US 2006011666A1
Authority
US
United States
Prior art keywords
liquid
alkyl
applicator
shaft
opening mechanism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/892,261
Inventor
Patrice Wurtz
Susan Leibenguth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MERIAL Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/892,261 priority Critical patent/US20060011666A1/en
Assigned to MERIAL LIMITED reassignment MERIAL LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEIBENGUTH, SUSAN, WURTZ, PATRICE
Priority to MXPA04009556 priority patent/MXPA04009556A/en
Priority to EP05731101A priority patent/EP1748930A4/en
Priority to PCT/US2005/010446 priority patent/WO2005094330A2/en
Priority to AU2005201472A priority patent/AU2005201472B2/en
Publication of US20060011666A1 publication Critical patent/US20060011666A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/10—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages having frangible closures
    • B65D47/106—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages having frangible closures with devices for removing frangible parts of the pouring element or of its closure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/09—Ampoules
    • B65D1/095—Ampoules made of flexible material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/10—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages having frangible closures

Definitions

  • patent law e.g., they allow for the inclusion of additional ingredients or steps that do not detract from the novel or basic characteristics of the invention, i.e., they exclude additional unrecited ingredients or steps that detract from novel or basic characteristics of the invention, and they exclude ingredients or steps of the prior art, such as documents in the art that are cited herein or are incorporated by reference herein, especially as it is a goal of this document to define embodiments that are patentable, e.g., novel, nonobvious, inventive, over the prior art, e.g., over documents cited herein or incorporated by reference herein.
  • the terms “consists of” and “consisting of” have the meaning ascribed to them in U.S. patent law; namely, that these terms are closed ended.
  • the present invention is directed to a new and useful apparatus for dispensing liquid agents. Specifically, the present invention is directed to an apparatus for applying liquids to the skin of an animal for the prevention and treatment of disease or parasite infestation.
  • a syringe includes a body in which the liquid is stored, a plunger that forces the liquid out of the body, and a needle or applicator tip for accurately locating the point of application of the liquid. While such a device is well suited for injection of liquids into the body, it is not well suited for topical application.
  • One obvious drawback of this device in the topical application situation is the apparent danger of puncturing the skin of the animal or the person applying the liquid when using a syringe with a needle.
  • Many liquid agents, which are intended for topical use can have harmful or irritating reactions when applied beneath the skin of the animal.
  • One device 50 which has come into some prominence lately, particularly in the application of topical flea and tick preventative agents, is a type of plastic pipette.
  • One common device 50 shown in FIG. 2 , comprises a storage chamber 52 formed of a flexible plastic material 56 and a semi or substantially rigid material 54 .
  • the device further comprises, a narrowed neck 58 , and a break away tip 60 .
  • Flexible materials typically have a thickness below about 100 ⁇ m and include for example polyesters, polyamides, polypropylenes, polyolefins, and aluminum foils.
  • the aluminium foils have a thickness of less than about 20 ⁇ m.
  • Rigid materials typically have a thickness of below about 200 ⁇ m and include for example, polyethylene terephthalate (PET), amorphous polyethylene terephthalate (APET), polyethylene terephthalate glycol (PETG), or crystalline polyethylene terephthalate (CPET), polyvinyl chloride (PVC), polypropylene (PP), cycloolefin copolymers such as that known under the tradename COC®, poly acrilo nitrile (PAN) such as that known under the tradename BAREX®, fluropolymer or chlorotrifluoroetheylene (CTFE) such as that known under the tradename ACLAR®, and aluminum foils up to about 100 ⁇ m.
  • PET polyethylene terephthalate
  • APET amorphous polyethylene terephthalate
  • PETG polyethylene terephthalate glycol
  • CPET crystalline polyethylene terephthalate
  • PVC polyvinyl chloride
  • PP polypropy
  • the tip 60 of the pipette 50 is broken off to allow for the free flow of the liquid agent from the storage chamber 52 to the skin of the animal via the neck 58 .
  • the pipette 50 is arranged on the animal so that the neck 58 of the pipette parts the animals hair, and the storage chamber 52 is squeezed to compress the flexible material 56 against the rigid material 54 and force the liquid agent through the neck 58 , and onto the skin of the animal.
  • break away tip 60 can be difficult to break due to the use of the rigid materials discussed above.
  • Many of the agents, particularly anti-flea and tick agents, can be very irritating when inadvertently applied to human skin, and pose an even greater danger if inadvertently splashed into the eyes or mouth of the user.
  • these break away tips typically require the use of two hands to open before the user can apply the liquid to the animal.
  • a sharp edge may be formed on the end of the neck by the severed end of the rigid material 54 . This edge can be sharp enough to injure either the animal or the user. Application of the liquid agent to an animal or user that has been cut by the sharp edge can be very irritating.
  • liquid agent applicator that is easy to open without potential for spraying the user, that ensures the liquid agent application to the skin and beneath the hair of the animal, and that does not retain a sharp edge after opening.
  • It is another advantageous embodiment of the present invention produce a liquid agent applicator that can be opened by a user single-handedly, does not have a likelihood of splashing the user with the liquid agent, and does not produce a sharp edge upon opening.
  • a liquid agent applicator having a collapsible reservoir for storing the liquid agent and a shaft having a lumen there through connected to the collapsible reservoir.
  • the liquid agent applicator includes an opening mechanism inserted into an orifice formed in one end of the shaft and a breakable seal formed between the opening mechanism and the shaft. Further, twisting of the opening mechanism relative to the shaft breaks the seal allowing egress of the liquid agent stored in the reservoir.
  • the liquid applicator includes a child resistant opening mechanism.
  • the child resistant opening mechanism includes a rigid stationary neck and a movable cap.
  • the child resistant opening mechanism also includes a septum for preventing the egress of liquid from the reservoir formed on the stationary neck, and a punch formed on the movable cap, for piercing the septum to allow the egress of liquid from the reservoir.
  • the child resistant opening mechanism also includes an interlock requiring two or more movements of the movable cap by the user, wherein upon completion of the two or more actions, the movable cap is movable along the stationary neck in the direction of the septum. And movement of the stationary cover in the direction of the septum causes the punch to pierce the septum and release the liquid agent.
  • FIG. 1 is a perspective view of a liquid applicator according to the present invention
  • FIG. 2 a is a front view of a prior art pipette
  • FIG. 2 b is a side view of a prior art pipette
  • FIG. 3 a is a cross-sectional view of a shaft of a pipette according to one embodiment of the present invention.
  • FIG. 3 b is a cross sectional view of a shaft of a pipette according to another embodiment of the present invention.
  • FIG. 4 is a cross-sectional view of a CR shaft according to one embodiment of the present invention.
  • FIG. 5 is side view of a CR shaft according to one embodiment of the present invention.
  • FIG. 6 is a perspective view of a liquid applicator with a CR shaft.
  • FIG. 7 is a perspective view of three examples of one embodiment of the present invention as formed by a thermoforming process.
  • FIG. 8 is a front view of three examples of one embodiment of the present invention as formed by a thermoforming process.
  • FIG. 1 A pipette according to the present invention is shown if FIG. 1 .
  • the pipette 10 includes a base or reservoir 12 , connected to a shaft 14 , and an opening mechanism 16 .
  • the shaft 14 has a lumen 24 extending there through fluidly connected to the reservoir 12 .
  • the pipette 10 is designed for easy, no-mess, one-handed use.
  • the base or reservoir 12 is advantageously formed with finger grips or notches 18 formed therein to assist the user in grasping the pipette 10 .
  • These grips 18 allow the pipette to be held by the user with only two fingers, and further enable the user to apply pressure to the reservoir 12 , of the pipette 10 , for application of the liquid stored therein using just these two fingers. Accordingly, the grips 18 assist the user by providing means for safe and effective one handed holding and use of the pipette 10 .
  • the reservoir 12 is advantageously shaped with a substantially flat or slightly concave bottom 20 , which enables the pipette 10 to be placed in an upright position on a flat surface such as a table or counter.
  • the bottom 20 represents a considerable advantage to the user in that he/she can open the pipette 10 and place it down without fear that the contents of the pipette will spill out. Particularly in use with animals and more particularly in the application of anti-flea and tick liquids such a feature is particularly useful. Often after opening a pipette there may be reason for the pipette to be place down on a table or counter.
  • the reservoir 12 is formed of a collapsible material that allows the user to apply pressure to the finger grips with just two fingers of one hand and force the fluid contained in the reservoir through the shaft 14 .
  • the reservoir 12 is formed of a material having sufficient rigidity that initial grasping of the reservoir 12 by the user will not compress the reservoir 12 sufficiently to cause the liquid agent to be expelled from the orifice of the shaft 14 .
  • To propel the liquid agent from the reservoir 12 through the shaft 14 and out the orifice requires an appreciable but not undue amount of force in excess of that required to grasp and hold the pipette 10 .
  • suitable plastic materials may be used to form the pipette 10 . Further these plastic materials may be formed as a single or monolayer, alternatively the plastic materials may be formed as a lamination of multiple plastic layers without departing from the scope of the present invention.
  • the opening mechanism 16 is formed so that twisting will remove it from the shaft 14 .
  • the opening mechanism 16 may be threaded like a bolt into the lumen 24 of the shaft 14 .
  • threads are formed on both the interior of the shaft, and the exterior of a plug 30 of the opening mechanism 16 .
  • the plug 30 may simply be inserted into the orifice formed at the end of the lumen 24 in the shaft 14 with sufficient force to prevent express of the fluid without removal of the plug. Twisting of the opening mechanism 16 allows the user to extract the plug 30 from the lumen 24 .
  • a plastic seal 25 can be formed between the plug 30 and the shaft 14 , preventing the egress of liquid out of the pipette 10 .
  • the seal 25 maybe formed, for example, of a narrowed thickness of plastic material.
  • the plastic material of the seal 25 may be formed so that twisting of the opening mechanism 16 will overcome the tensile strength of the material causing it to shear, thereby breaking the seal.
  • the plug 30 can be removed from the shaft 14 and an orifice is created in the shaft 14 , which allows for dispensation of the fluid agent from the pipette 10 .
  • the seal 25 is formed of the same plastic material as the plug 30 and the shaft 14 .
  • opening mechanism 16 is grasped by as few as two of the user's fingers, while the pipette 10 rests in the palm of the user's hand.
  • the pipette 10 is opened one-handed. Enabling one-handed opening of the pipette simplifies the application of fluids such as flea and tick repellants to dogs and cats.
  • One problem with pipettes currently used in such applications, as shown in FIG. 2 is that they, typically require two hands to open. This in turn may require a second person to assist in holding the animal while the user opens the pipette. Alternatively, a user may attempt to hold the animal between their knees while opening the pipette.
  • twist top opening mechanism 16 prevents the formation of a sharp edge at the tip 22 of the shaft 14 .
  • use of many of the prior art devices resulted in the formation of a sharp plastic edge that could injure the animal during application.
  • many of the topical use liquid agents can be very irritating if administered into the skin of the animal or the user, the likelihood of scratching the skin presents a problem for the user and the animal.
  • the sealing of the shaft 14 of the pipette 10 to the plug 30 is accomplished using the plastic materials of the plug 30 and the shaft 14 to form a seal. The seal has a reduced tensile strength in comparison to the plug 30 and the shaft 14 that can be sheared when the opening mechanism 16 is twisted.
  • a further feature of this embodiment is that the seal may be formed in the lumen 24 .
  • the placement of the seal at the tip 22 of the shaft 14 may not necessarily result in the prevention of a sharp edge forming on the tip 22 upon the removal of the opening mechanism 16 from the shaft 14 . Accordingly, by forming the seal between the shaft 14 and the plug 30 of the opening mechanism 16 inside the lumen 24 , no sharp edge will be formed on the tip 22 . As a result the dangers associated with such a sharp edge are greatly reduced and there is little likelihood of injury to either the user or the animal.
  • the shaft 14 of the pipette 10 is advantageously formed of a substantially rigid material that resists bending.
  • the shaft 14 is also formed with a long neck to assist in proper dosing.
  • the long neck and resistance to bending provide beneficial support for the pipette 10 during application of the fluid agent on the animal.
  • the stiffness or resistance to bending and the long neck allow the user to easily part the animal's hair or fur for application directly on the animals skin.
  • the shaft 14 is between 1 and 5 cm in length.
  • the CR shaft 44 includes a rigid stationary neck 45 , a movable cap 48 , and a septum 46 .
  • the septum 46 acts as a seal on the pipette 10 preventing the egress of a liquid agent contained therein.
  • the movable cap 48 includes a punch 49 .
  • the punch 49 includes a piercing tip of sufficient rigidity to allow the punch 49 to pierce the septum 46 .
  • the piercing of the septum 46 allows for the free flow of the liquid agent from the reservoir 12 of the pipette 10 to the CR shaft, 44 .
  • the CR shaft 44 also includes a means for preventing a child from opening the pipette 10 .
  • This means for preventing a child from opening the pipette 10 may be of a type know in the art.
  • the prevention means can include requiring depression or extension of the movable cap 48 vertically to a first position and twisting of the cover while in this first position to a rotational stop point. Once the rotational stop point is reached depression of the movable cap 48 allows the punch 49 to pierce the septum 46 .
  • the piercing of the septum 46 allows fluid communication of the liquid agent in the pipette 10 through the lumen and onto the animal.
  • Other means of preventing a child from opening the pipette 10 will be known to those of skill in the art and are therefore considered within the scope of the present invention.
  • the cap 48 may include a lumen (not shown) which extends through the punch 49 . This allows for egress of fluid from the pipette 10 after piercing of the septum 46 .
  • thermoforming One method of manufacturing such a pipette 10 is called thermoforming.
  • sheets of a desired plastic material are fed into a press. These sheets may be formed of one or more layers of plastic material.
  • the press contains a mold of the shape to be formed for example, the reservoir 12 of the pipette 10 .
  • the press contains a mold of the shape to be formed for example, the reservoir 12 of the pipette 10 .
  • the air pressure forces a portion of the now heated plastic sheets into the molds to form the shape of the reservoir 12 .
  • the heat acts to seal the two sheets of plastic material together to form a single plastic sheet having a reservoir 12 .
  • the heat is removed, and upon cooling, reservoir 12 may be cut from the plastic sheet.
  • FIGS. 7 and 8 show three examples of the present invention formed by a thermoforming process.
  • the reservoir 12 can then be filled with the desired liquid agent, for example a flea and tick repellant for use with domestic animals such as dogs and cats.
  • the shaft 14 with opening mechanism 16 is inserted into an opening in the reservoir 12 . Further application of heat to the opening in the reservoir 12 acts to seal the reservoir 12 to the shaft 14 , thereby creating a sealed pipette 10 which can then be cut from the sheet of plastic for packaging and sale.
  • the base 12 is formed and the shaft 14 inserted therein. After application of heat to the base 12 and shaft 14 combination, the liquid agent is added via an orifice in the end of the shaft 14 . After filling the opening mechanism 16 is inserted into the orifice. Application of yet another source of heat seals the opening mechanism 16 to the shaft 14 .
  • any liquid agent may be stored and administered to the animal or human by this applicator.
  • Preferred liquid agents are topical pharmaceutical or veterinary formulations.
  • Therapeutic agents which are present in the formulations, include, for example, substances or combination of substance such as, for example, antiviral, antibacterial, antiparasitic, antifungal substances and combinations thereof.
  • the therapeutic agent may further be a substance, capable of acting as a stimulant, sedative, hypnotic, analgesic, anticonvulsant, and the like. Examples of these therapeutic agents include, but are not limited to: Anti-inflammatory agents such as hydrocortisone, prednisone, fludrotisone, triamcinolone, dexamethasone, betamethasone and the like.
  • Anti-bacterial agents such as penicillins, cephalosporins, vancomycin, bacitracin, polymycins, tetracyclines, chloramphenicol, erythromycin, streptomycin, and the like.
  • Antiparasitic agents such, as quinacrine, chloroquine, quinine, and the like.
  • Antifungal agents such as nystatin, gentamicin, miconazole, tolnaftate, undecyclic acid and its salts, and the like.
  • Antiviral agents such as vidarabine, acyclovir, ribarivin, amantadine hydrochloride, iododeoxyuridine, dideoxyuridine, interferons and the like.
  • Antineoplastic agents such as methotrexate, 5-fluorouracil, bleomycin, tumor necrosis factor, tumor specific antibodies conjugated to toxins, and the like.
  • Analgesic agents such as salicylic acid, salicylate esters and salts, acetaminophen, ibuprofen, morphine, phenylbutazone, indomethacin, sulindac, tolmetin, zomepirac, and the like.
  • Local anaesthetics such as cocaine, benzocaine, novocaine, lidocaine, and the like.
  • Vaccines or antigens, epitopes, immunogens of human or animal pathogens, such as hepatitis, influenza, measles, mumps, rubella, hemophilus, diphtheria, tetanus, rabies, polio, as well as veterinary vaccines and the like.
  • Central nervous system agents such as tranquilizers, sedatives, anti-depressants, hypnotics, ⁇ -adrenergic blocking agents, dopamine, and the like.
  • Growth factors such as colony stimulating factor, epidermal growth factor, erythropoietin, fibroblast growth factor, neural growth factor, human growth hormone, platelet derived growth factor, insulin-like growth factor, and the like.
  • Hormones such as progesterone, estrogen, testosterone, follicle stimulating hormone, chorionic gonadotrophin, insulin, endorphins, somatotropins and the like.
  • Antihistamines such as diphenhydramine, chlorpheneramine, chlorcyclizine, promethazine, cimetidine, terfenadine, and the like.
  • Cardiovascular agents such as verapamil hydrochloride, digitalis, streptokinase, nitroglycerine paparefine, disopyramide phosphate, isosorbide dinitrate, and the like.
  • Anti-ulcer agents such as cimetidine hydrochloride, sopropamide iodide, propantheline bromide, and the like.
  • Bronchodilators such as metaproternal sulfate, aminophylline, albuterol, and the like.
  • Vasodilators such as theophylline, niacin, nicotinate esters, amylnitrate, minoxidil, diazoxide, nifedipine, and the like.
  • the therapeutic agents which are used in the formulations for the inventive applicator can be well known to the practitioner to which this invention pertains.
  • Classes of therapeutic agents contemplated by the inventive formulations include insecticides, acaricides, parasiticides, growth enhancers, and oil-soluble, nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Specific classes of compounds which fall within these classes include, for example, avermectins, milbemycins, nodulisporic acid and its derivatives, estrogens, progestins, androgens, substituted pyridylmethyl derivatives, phenylpyrazoles, and COX-2 inhibitors.
  • the avermectin and milbemycin series of compounds are potent anthelmintic and antiparasitic agents against a wide range of internal and external parasites.
  • the compounds which belong to this series are either natural products or are semi-synthetic derivatives thereof.
  • the structure of these two series of compounds are closely related and they both share a complex 16-membered macrocyclic lactone ring; however, the milbemycin do not contain the aglycone substitutent in the 13-position of the lactone ring.
  • the natural product avermectins are disclosed in U.S. Pat. No.
  • bioactive agents such as avermectins or ivermectin can be used in combination with other bioactive agents; and, with respect to a vermectins, ivermectin, and bioactive agent combinations, reference is made to Kitano, U.S. Pat. No. 4,468,390, Beuvry et al., U.S. Pat. No. 5,824,653, von Bittera et al., U.S. Pat. No. 4,283,400, European Patent Application 0 007 812 A1, published June 2, 1980, U.K. Patent Specification 1 390 336, published Apr. 9, 1975, European Patent Application 0 002 916 A2, Ancare New Zealand Patent No. 237 086, Bayer New Zealand Patent 176193, published Nov. 19, 1975, inter alia.
  • Nodulisporic acid and its derivatives are a class of acaricidal, antiparasitic, insecticidal and anthelminitic agents known to a practitioner of the art. These compounds are used to treat or prevent infections in humans and animals. These compounds are described, for example, in U.S. Pat. No. 5,399,582 and WO 96/29073.
  • Especially preferred therapeutic agents include nodulisporic acid compounds A, B, and C as well as nodulisporic acid derivatives of the formula: wherein
  • R 1 is (1) hydrogen
  • R 2 , R 3 , and R 4 are independently OR a , OCO 2 R b , OC(O)NR c R d ; or
  • R 1 and R 2 represent ⁇ O, ⁇ NOR a or ⁇ N—NR c R d ;
  • R 5 and R 6 are H;
  • R 5 and R 6 together represent —O—
  • R 7 is (1) CHO, or
  • R 8 is (1) H
  • R 9 is (1) H, or
  • R 10 is (1) CN
  • R a is (1) hydrogen
  • R b is (1) H
  • R c and R d are independently selected from R b ; or
  • R c and R d together with the N to which they are attached form a 3- to 10-member ring containing 0 to 2 additional heteroatoms selected from O, S(O) m , and N, optionally substituted with 1 to 3 groups independently selected from R g , hydroxy, thioxo and oxo;
  • R e is (1) halogen
  • R f is (1) alkyl
  • R g and R h are independently
  • R g and R h together with the N to which they are attached form a 3- to 7-member ring containing 0 to 2 additional heteroatoms selected from O, S(O) m , and N, optionally substituted with 1 to 3 groups independently selected from R e and oxo;
  • R i is (1) hydrogen
  • n 0 to 2;
  • v is 0 to 3;
  • R x is selected from the group consisting of: H, CH 3 , CH 2 CH 3 , C(CH 3 ) 3 , CH 2 CH 2 CH 3 , CH 2 CH 2 OH, CH(CO 2 CH 3 )OH, CH 2 CO 2 CH 3 , CH 2 CH(OCH 2 CH 3 ) 2 , CH 2 CH 2 OCH 2 CH 2 OH, CH(CH 3 )(CH 2 ) 3 C(CH 3 ) 2 OH, (CH 2 ) 3 OH, (CH 2 ) 4 OH, (CH 2 )SOH, CH(CH 2 OH)CH 2 CH 3 , NHC(CH 3 ) 3 , CH 2 CN, (CH 2 ) 6 OH, CH 2 CH(OH)CH 3 , CH(CH 2 OH)CH 2 CH 2 CH 3 , CH 2 CH 2 SCH 3 , CH 2 CH 2 SCH 2 CH 3 , CH 2 CONH, CH(CH 3 )(CH 2 OH) 2 , CH 2
  • An e specially preferred nodulisporamide derivative is one wherein R X is with t-butyl (or “nodulisporamide).
  • insecticides may be used in this invention.
  • One example of this class include substituted pyridylmethyl derivatives such as imidacloprid.
  • Agents of this class are described, for example, in U.S. Pat. No. 4,742,060 or in EP 892,060.
  • Pyrazoles such as phenylpyrazoles and N-arylpyrazoles are another class of insecticides which possess excellent insecticidal activity against all insect pests including blood-sucking pests such as ticks, fleas etc., which are parasites on animals.
  • This class of agents kills insects by acting on the gamma-butyric acid receptor of invertebrates.
  • Such agents are described, for example, in U.S. Pat. No. 5,567,429, U.S. Pat. No. 5,122,530, EP 295,117, and EP 846686 A1 (or Banks GB 9625045, filed Nov. 30, 1996 also believed to be equivalent to U.S. Ser. No. 309,229, filed Nov. 17, 1997). It would be well within the skill level of the practitioner to decide which individual compounds can be used in the inventive formulations.
  • Another preferred 1-N-arylpyrazole derivative is a compound wherein the ring formed by the divalent alkylene substituent representing R 5 and R 6 and the nitrogen atom to which R 5 and R 6 are attached has 5, 6 or 7 members or wherein R 1 is CN, R 3 is C 1 -C 6 -haloalkyl, R 4 is NH 2 , R 11 and R 12 are, independently of one another, hydrogen or halogen and R 13 is C 1 -C 6 -haloalkyl.
  • Another 1-N-arylpyrazole derivatives to be used in topical formulations that may be administered by the present invention are those compounds of formula (III): wherein:
  • the alkyl groups of the definition of the compounds (1) of the formula (I) generally comprise from 1 to 6 carbon atoms.
  • the ring formed by R 5 and R 6 and the nitrogen atom to which they are attached is generally a 5-, 6- or 7-membered ring.
  • alkyl and alkoxy groups are generally lower alkyl and alkoxy groups, that is having from one to six carbon atoms, preferably from one to four carbon atoms.
  • the haloalkyl, haloalkoxy and alkylamino groups have from one to four carbon atoms.
  • the haloalkyl and haloalkoxy groups can bear one or more halogen atoms; preferred groups of this type include —CF 3 and —OCF 3 .
  • Cycloalkyl groups generally have from 3 to 6 carbon atoms, preferably from 3 to 5 carbon atoms, and may be substituted by one or more halogen atoms.
  • Alkenyl, haloalkenyl, alkynyl, and haloalkynyl groups generally contain from 3 to 5 carbon atoms.
  • aryl is generally meant phenyl, pyridyl, furyl, and thiophenyl, each of which is optionally substituted by one or more halogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, hydroxy, amino, alkylamino or dialkylamino.
  • substituted alkyl alkyl which is substituted by, for example, one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or —S(O) m R 115 ; or alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R 115 is alkyl or haloalkyl and m is zero, one or two.
  • alkyl groups are generally substituted by from one to five halogen atoms, preferably from one to three halogen atoms. Chlorine and fluorine atoms are preferred.
  • cycloalkylalkyl is cyclopropylmethyl
  • an example of cycloalkoxy is cyclopropyloxy
  • the alkyl and haloalkyl groups on nitrogen may be chosen independently of one another.
  • a preferred class of compounds of formula (I) comprises the compounds such that R 1 is CN, R 3 is haloalkyl, R 4 is NH 2 , R 11 and R 12 are, independently of one another, a halogen atom and R 13 is haloalkyl.
  • X is C—R 12 .
  • a compound of formula (I) which is very particularly preferred in the invention is 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole or fipronil.
  • IGR compounds are another class of insecticides or acaricides, which are therapeutic agents that may be administered by the inventive applicator.
  • Compounds belonging to this group are well known to the practitioner and represent a wide range of different chemical classes. These compounds all act by interfering with the development or growth of the insect pests.
  • Compounds with an ovicidal and/or larvicidal effect on the immature stages of various ectoparasites are already known, for example from U.S. Pat. No. 5,439,924.
  • IGR compounds which act either by blocking the development of the immature stages (eggs and larvae) into adult stages, or by inhibiting the synthesis of chitin.
  • Insect growth regulators are described, for example, in U.S. Pat. No. 3,748,356; U.S. Pat. No. 3,818,047; U.S. Pat. No. 4,225,598; U.S. Pat. No. 4,798,837; and U.S. Pat. No. 4,751,225, as well as in EP 179,022 or U.K. 2,140,010.
  • French Patent No. A-2,713,889 generally describes an IGR combination comprising at least one compound with juvenile hormone activity and chitin synthesis inhibitors, with at least one of three N-arylpyrazole compounds, in particular fipronil or thiofipronil, to control many harmful insects belonging to very varied orders.
  • IGR compounds which may be used in this invention include compounds which mimic juvenile hormones, in particular:
  • Chitin-synthesis inhibitors also include compounds such as 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-((trifluoromethyl))phenylurea, 1 -(2,6-difluorobenzoyl)-3-(2-fluoro-4-(1,1,2,2-tetrafluoroethoxy))phenylurea and 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-trifluoro-methyl)phenylurea.
  • Novaluron Isagro, Italian company
  • IGR compound is also an example of an IGR compound.
  • Preferred IGR compounds include methoprenes, pyriproxyfens, hydroprene, cyromazine, lufenuron, 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl)phenylurea and novaluron.
  • Estrogens, progestins, and androgens refers to classes of chemical compounds which are also well known to a practitioner in this art.
  • estrogens and progestins are among the most widely prescribed drugs and are used, for example, alone or in combination for contraception or hormone replacement therapy in post menopausal women.
  • Estrogens and progestins occur naturally or are prepared synthetically.
  • This class of compounds also includes estrogens or progesterone receptor antagonists.
  • Antiestrogens, such as tamoxifen and clomiphene are used to treat breast cancer and infertility.
  • Antiprogestives are used as contraceptives and anticancer drugs, as well as to induce labor or terminate a pregnancy.
  • the androgens and antiandrogens structurally related to the estrogens and progestins as they are also biosynthesized from cholesterol. These compounds are based on testosterone. Androgens are used for hypogonadism and promote muscle development. Antiandrogens are used, for example, in the management of hyperplasia and carcinoma of the prostate, acne, and male pattern baldness as well as in the inhibition of the sex drive in men who are sex offenders. Estrogen, progestins, and androgens are described, for example, in “Goodman & Gilman's The Pharmacological Basis of Therapeutics,” 9 th ed., J. G. Handman and L. Elimbird, eds., Ch.
  • Estrogens, progestins and androgens are also used in animal husbandry as growth promoters for food animals. It is known in the art that compounds of these classes act as growth-promoting steroids in animals such as cattle, sheep, pigs, fowl, rabbits, etc. Delivery systems to promote the growth of animals are described, for example, in U.S. Pat. No. 5,401,507, U.S. Pat. No. 5,288,469, U.S. Pat. No. 4,758,435, U.S. Pat. No. 4,686,092, U.S. Pat. No. 5,072,716 and U.S. Pat. No. 5,419,910.
  • NSAIDs are well known in the art.
  • the classes of compounds which belong to this group include salicylic acid derivatives, para-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids (fenamates), enolic acids, and alkanones.
  • NSAIDs exert their activity by interfering with prostaglandin biosynthesis by irreversibly or reversibly inhibiting cycloxygenase.
  • COX-2 inhibitors which act by inhibiting the COX-2 receptor.
  • Compounds of this group possess analgesic, antipyretic and nonsteroidal anti-inflammatory properties.
  • COX-2 inhibitors include 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one or 3-(cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one, including the polymorphic B form of this compound, and the pharmaceutically acceptable salts or hydrates of these compounds.
  • Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one is characterized by the following parameters cristalline system Trigonal space group R-3 Description hexagonal unit-cell dimensions a ( ⁇ ) 18.183 b ( ⁇ ) 18.183 c ( ⁇ ) 26.950 ⁇ (°) 90 ⁇ (°) 90 ⁇ (°) 120 unit-cell volume ( ⁇ 3 ) 7716.5 number of molecules per unit-cell Z 18 Temperature of measurement (° K) 293 calculated specific gravity 1.303 weight absorption coefficient (cm ⁇ 1 ) 2.11
  • Macrolides are a class of antibiotics which contain a many-membered lactone ring to which are attached one or more deoxy sugars. Macrolides are generally bacteriostatic, but have been shown to be bacteriocidal in high concentration against very susceptible organisms. Macrolides are most effective against gram-position cocci and bacilli, although they do possess some activity against some gram-negative organism. Macrolides exert their bacteriostatic activity by inhibiting bacterial protein synthesis by binding reversibly to the 50 S ribosomal subunit. (“Goodman & Gillman's the Pharmacological Basis of Therapeutics,” 9th ed., J. G. Hadman & L. E. Limbird, eds., ch. 47, pp. 1135-1140, McGraw-Hill, New York (1996)).
  • the macrolides as a class are colorless and usually crystalline.
  • the compounds are generally stable in near neutral solution, but they only have limited stability in acid or base solutions. The reason for this is because the glycosidic bonds hydrolyze in acid and the lactone ring saponifies in base (“Principles of Medicinal Chemistry,” 2nd ed., W. F. Foye, ed., ch. 31, pp. 782-785, Lea & Febiger, Philadelphia (1981)).
  • the macrolide anthelmintic compounds contemplated for use in the present invention are also well known to a practitioner of this art. These compounds include avermectins and milbemycins discussed above. Non-limiting examples of compounds belonging to this class are represented by the following structure: where the broken line indicates a single or a double bond at the 22,23-positions;
  • Additional compounds are avermectin Bla/Blb (abamectin), 22,23-dihydro avermectin Bla/Blb (ivermectin) and the 4′′-acetylamino-5-ketoximino derivative of avermectin Bla/Blb. Both abamectin and ivermectin are approved as broad-spectrum antiparasitic agents.
  • the 4′′-acetyl amino-5-ketoximino derivatives of avermectin Bla/Blb has the following structural formula: where R 2 is isopropyl or sec-butyl.
  • the avermectin products are generally prepared as a mixture of at least 80% of the compound where R 2 is sec-butyl and no more than 20% of the compound where R 2 is isopropyl.
  • Other known avermectins include ememectin, eprinomectin and doramectin.
  • Preferred milbemycin compounds which may be used as therapeutic agents include milbemycin ⁇ i and moxidectin.
  • the monosaccharide avermectin derivatives are also useful in combination with the present invention, especially where an oxime substitution is present on the 5-position of the lactone ring.
  • Such compounds are described, for example, in EP 667,054.
  • Also contemplated are all pharmaceutical and veterinary acceptable acid or base salt forms of these compounds as well as the corresponding ester and amide derivatives of these compounds, where applicable.
  • Specific compounds which belong to this class of macrolide antiparasitic agents are well known to the practitioner of this art.
  • the bioactive agent in the present invention can be a macrolide, as macrolides are soluble in many organic solvents but are only slightly water soluble.
  • Macrolides as a class include the erythromycin and its derivatives as well as other derivatives such as the azalides.
  • Erythromycin (MW 733.94 daltons) is the common name for a macrolide antibiotic produced by the growth of a strain of Streptomyces erythreous. It is a mixture of three erythromycins, A, B and C consisting largely of erythromycin A.
  • Erythromycin has a broad and essentially bacteriostatic action against many Gram-positive and some Gram-negative bacteria as well as other organisms including mycoplasmas, spirochetes, chlamydiae and rickettsiae. In humans, it finds usefulness in the treatment of a wide variety of infections. It finds wide application in veterinary practice in the treatment of infectious diseases such as pneumonias, mastitis, metritis, rhinitis, and bronchitis in cattle, swine and sheep.
  • erythromycins include carbomycin, clarithromycin, josamycin, leucomycins, midecamycins, mikamycin, miokamycin, oleandomycin, pristinamycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, tylosin, troleandomycin, and virginiamycin.
  • carbomycin is a mixture of carbomycin A and carbomycin B.
  • Leucomycin exists as a mixture of components A 1 , A 2 , A 3 , A 9 , B 1 -B 4 , U and V in various proportions.
  • Component A 3 is also known as josamycin and leucomycin V is also known as miokomycin.
  • the major components of the midecamycins is midecamycin A and the minor components are midecamycins A 2 , A 3 and A 4 .
  • mikamycin is a mixture of several components, mikamycin A and B.
  • Mikamycin A is also known as virginiamycin M 1 .
  • Pristinamycin is composed of pristinamycins I A , I B , and I C , which are identical to virginiamycins B 2 , B 13 and B 2 respectively, and pristinamycin II A and II B , which are identical to virginiamycin M 1 and 26,27-dihydrovirginiamycin M 1 .
  • Spiramycin consists of three components, spiromycin I, II, and III. Virginiamycin is composed of virginiamycin S 1 and virginiamycin M 1 . All these components may be used in this invention. Sources of these macrolides are well known to the practitioner and are described in the literature in references such as “The Merck Index,” 12th ed., S. Budarari, ed., Merck & Co., Inc., Whitehouse Station, N.J. (1996).
  • the azalides are semisynthetic macrolide antibiotics related to erythromycin A and exhibit similar solubility characteristics.
  • the structure of azithromycin is known.
  • Useful azalide compounds are disclosed in EP 508699, herein incorporated by reference.
  • the corresponding basic and acid addition salts and ester derivatives of the macrolides compounds are also contemplated for use in this invention. These salts are formed from the corresponding organic or inorganic acids or bases. These derivatives include the customary hydrochloride and phosphate salts as well as the acetate, propionate and butyrate esters. These derivatives may have different names.
  • the phosphate salt of oleandomycin is matromycin and the triacetyl derivative is troleandomycin.
  • Rokitamycin is leucomycin V 4-B-butanoate, 3B-propionate.
  • the therapeutic agents nodulisporamide derivatives or 1-N-arylpyrazoles may be combined with other insecticides, parasiticides, and acaricides.
  • Such combinations include anthelminitic agents, such as those discussed above which include ivermectin, avermectin, and emamectin, as well as other agents such as thiabendazole, praziquantel, febantel or morantel.
  • other combinations may include imidicloprid or a COX-2 inhibitor.
  • topical formulations that are preferred include those comprising:
  • compositions comprising:
  • spot-on or pour-on formulations are those comprising, for example, comprising from 0.05 to 25% weight/volume, relative to the total solution, of a compound of the formula: wherein:
  • spot-on or pour-on formulations include: synergistic spot-on compositions for the long lasting protection against ectoparasites on mammals which comprises synergistic amounts
  • a fluid vehicle comprising at least one customary spot-on formulation adjuvant; or a composition comprising
  • R 2 is S(O) n R 3 or 4,5-dicyanoimidazol-2-yl or haloalkyl;
  • composition comprises
  • Suitable macrocyclic lactones include a vermectins, abamectin, doramectin, moxidectin, and milbemycin.
  • Frontline® is a spot-on product comprises fipronil, ethanol, polvidone, Tween 80, butylhydroxytoluene, butlyhydroxyanisole and diethylene glycol monomethylether.
  • Frontline Plus® contains the same ingredients as Frontline® except that it further includes (S)-methoprene.
  • Revolution® is a spot-on product comprising selamectin in isopropanol, polyvidone, Tween 80, butylhydroxytoluene, dipropylene glycol monomethylether.
  • topical formulations used in the present invention may include other formulations adjuvants well know to a practitioner in this art.
  • Non-limiting examples of these additives are as follows:
  • the thickeners are well known to a practitioner of this art and may be added to these formulations.
  • Compounds which function as thickeners include, for example, povidone, maltodextrin, polydextrate, EMDEX (dextrates), carboxypolymethylene (Carbomer®), polyethylene glycol and celluloses, such as hydroxypropyl celluloses.
  • An especially preferred thickener is povidone.
  • Thickeners may be present in amounts of from about 0.1% to about 25%.
  • Opacifiers may be added to absorb and/or reflect certain light and/or energy of certain wavelengths and may thus enhance the stability of the formulations.
  • Opacifiers include, for example, zinc oxide or titanium dioxide and may be present in amounts from about 0.5 to 2.5%. Titanium dioxide is especially preferred. These compounds are well known to practitioners of this art.
  • the formulations may contain other inert ingredients such as antioxidants, preservatives, or pH stabilizers. These compounds are well known in the formulation art.
  • Antioxidant such as an alpha tocopheral, ascorbic acid, ascrobyl palmitate, fumeric acid, malic acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), monothioglycerol and the like, may be added to the present formulation.
  • the antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0%, based upon total weight of the formulation, with about 0.05 to about 1.0% being especially preferred.
  • Preservatives such as the parabens (methylparaben and/or propylparaben), are suitably used in the formulation in amounts ranging from about 0.01 to about 2.0%, with about 0.05 to about 1.0% being especially preferred.
  • Other preservatives include benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and the like. Preferred ranges for these compounds include from about 0.01 to about 5%.
  • Colorants may be added to the formulations.
  • Specific colorants include, for example, dyes, an aluminum lake, caramel, colorant based upon iron oxide or a mixture of any of the foregoing.
  • organic dyes and titanium dioxide are especially useful. Preferred ranges include from about 0.1% to about 25%.
  • Solvents for the formulations would be readily known in the art and include, for example, glycerol formal, 1-methylpyrrolidone (NMP), propylene, glycol, polyethylene glycol, benzyl alcohol, mixtures of glyceride/triglyceride and their derivatives, such as caprilic/capric acid triglyceride, or fatty acid esters (miglyol products) diethylene glycol monoethyl ether (transcutol®), lauroglycol 90, dimethylfomamide (DMF), dimethyl sulfoxide (DMSO) and mixtures of these solvents.
  • NMP 1-methylpyrrolidone
  • propylene glycol
  • polyethylene glycol polyethylene glycol
  • benzyl alcohol mixtures of glyceride/triglyceride and their derivatives
  • fatty acid esters milyol products
  • diethylene glycol monoethyl ether transcutol®
  • lauroglycol 90 dimethylfom
  • Administration of the inventive formulation may be intermittent in time and may be administered daily, weekly, biweekly, monthly, bimonthly, quarterly, or even for longer durations of time.
  • the time period between treatments depends upon factors such as the parasite(s) being treated, the degree of infestation, the type of mammal or bird and the environment where it resides. It is well within the skill level of the practitioner to determine a specific administration period for a particular situation.
  • Spot-on and pour-on formulations may be prepared by dissolving the therapeutic agents into the pharmaceutically or veterinary acceptable vehicle.
  • the spot-on formulation can be prepared by encapsulation of the active ingredient to leave a residue of the therapeutic agent on the surface of the animal.
  • These formulations will vary with regard to the weight of the therapeutic agent in the combination depending on the therapeutic agent, the species of host animal to be treated, the severity and type of infection and the body weight of the host.
  • the compounds may be administered continuously, particularly for prophylaxis, by known methods.
  • a dose of from about 0.001 to about 10 mg per kg of body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but, of course, there can be instance where higher or lower dosage ranges are indicated and such are within the scope of this invention. It is well within the routine skill of the practitioner to determine a particular dosing regimen for a specific therapeutic agent for a specific host and parasite.
  • a single formulation containing for example, a 1-N-arylpyrazole derivative in a substantially liquid carrier and in a form which makes possible a single application, or an application repeated a small number of times, will be administered to the animal over a highly localized region of the animal, preferably between the two shoulders. Most preferably, this localized region has a surface area of less than 10 cm, especially between 5 and 10 cm 2 area.
  • the dosage values which are thus indicated are average values which may vary within a wide range.
  • a formulation having defined doses of 1-N-arylpyrazole-type derivative and of an IGR compound will be administered to animals having relatively different weights. Consequently, the doses actually applied are often smaller or larger by a factor which may be up to 2, 3 or 4 relative to the preferred dose, without entailing any toxic risk for the animal in the case of an overdose, and while at the same time retaining real efficacy, possibly of shorter duration, in the case of an underdose.
  • the spot-on formulations that are used in present invention provide for the topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to a spot on the animal, generally between the two shoulders (solution of spot-on type). It has been discovered that the inventive formulations are especially active against parasites when the formulations are applied to mammals and birds, especially poultry, dogs, cats, sheep, pigs, cattle zebras, horses, donkeys, mice, chipmunks and tree squirrels.
  • the pharmaceutically or veterinary-acceptable acid or base salts where applicable, of the therapeutic agents provided for herein.
  • the term “acid” contemplates all pharmaceutically or veterinary acceptable inorganic or organic acids.
  • Inorganic acids include mineral acids such as hydrohalic acids, such as hydrobromic and hydrochloric acids, sulfuric acids, phosphoric acids and nitric acids.
  • Organic acids include all pharmaceutically or veterinary-acceptable aliphatic, alicyclic and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids and fatty acids.
  • Preferred acids are straight chain or branched, saturated or unsaturated C 1 -C 20 aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C 6 -C 12 aromatic carboxylic acids.
  • acids are carbonic acid, formic acid, fumaric acid, acetic acid, propionic acid, isopropionic acid, valeric acid, ⁇ -hydroxy acids, such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane sulfonic acid, and salicylic acid.
  • dicarboxylic acids include oxalic acid, malic acid, succinic acid, tataric acid and maleic acid.
  • a tricarboxylic acid is citric acid.
  • Fatty acids include all pharmaceutically or veterinary-acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms. Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylsteric acid.
  • Other acids include gluconic acid, glycoheptonic acid and lactobionic acid.
  • bases contemplates all pharmaceutically or veterinary acceptable inorganic or organic bases.
  • bases include, for example, the alkali metal and alkaline earth metal salts, such as the lithium, sodium, potassium, magnesium or calcium salts.
  • Organic bases include the common hydrocarbyl and heterocyclic amine salts, which include, for example, the morpholine and piperidine salts.
  • the organic solvent for the liquid carrier vehicle will preferably have a dielectric constant of between about 10 and about 35, preferably between about 20 and about 30, the content of this solvent in the overall composition preferably representing the remainder of 100% of the composition. It is well within the skill level of the practitioner to select a suitable solvent on the basis of these parameters.
  • the organic cosolvent for the liquid carrier vehicle will preferably have a boiling point of less than about 100° C., preferably of less than about 80° C., and will have a dielectric constant of between about 10 and about 40, preferably between about 20 and about 30; this cosolvent can advantageously be present in the composition according to a weight/weight (W/W) ratio with respect to the solvent of between about 1/15 and about 1/2; the cosolvent is volatile in order to act in particular as drying promoter and is miscible with water and/or with the solvent. Again, it is well within the skill level of the practitioner to select a suitable solvent on the basis of these parameters.
  • the organic solvent for the liquid carrier includes the commonly acceptable organic solvents known in the formulation art. These solvents may be found, for example, in Remington Pharmaceutical Science, 16 th Edition (1986). These solvents include, for example, acetone, ethyl acetate, methanol, ethanol, isopropanol, dimethylformamide, dichloromethane or diethylene glycol monoethyl ether (Transcutol). These solvents can be supplemented by various excipients according to the nature of the desired phases, such as C 8 -C10 caprylic/capric triglyceride a hydrogenated or fractionated coconut oil (Estasan or Miglyol 812), oleic acid or propylene glycol.
  • C 8 -C10 caprylic/capric triglyceride a hydrogenated or fractionated coconut oil (Estasan or Miglyol 812), oleic acid or propylene glycol.
  • the liquid carrier may also comprise a microemulsion.
  • Microemulsions are also well suited as the liquid carrier vehicle. Microemulsions are quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids.
  • Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase.
  • the size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions).
  • the interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously.
  • the oily phase can in particular be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such compounds.
  • the oily phase preferably comprises triglycerides and more preferably medium-chain triglycerides, for example C 8 -C 10 caprylic/capric triglyceride.
  • the oily phase will represent, in particular, from about 2 to about 15% more, particularly from about 7 to about 10%, preferably from about 8 to about 9%, V/V of the microemulsion.
  • Suitable oils for the oily phase are known in the art and are described, for example, in U.S. Pat. No. 6,036,394; U.S. Pat. No. 5,580,574; U.S. Pat. No. 6,174,540 and WO 97/37653, herein incorporated by reference.
  • the aqueous phase includes, for example, water or glycol derivatives, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol. Propylene glycol, diethylene glycol monoethyl ether and dipropylene glycol monoethyl ether are especially preferred. Generally, the aqueous phase will represent a proportion from about 1 to about 4% V/V in the microemulsion.
  • Surfactants for the microemulsion include diethylene glycol monoethyl ether, dipropylene glycol monomethyl ether, polyglycolysed C 8 -C 10 glycerides or polyglyceryl-6 dioleate.
  • the cosurfactants include short-chain alcohols, such as ethanol and propanol.
  • the cosurfactant to surfactant ratio will preferably be from about 1/7 to about 1/2. There will preferably be from about 25 to about 75% V/V of surfactant and from about 10 to about 55% V/V of cosurfactant in the microemulsion.
  • co-solvents are also well known to a practitioner in the formulation art.
  • Preferred co-solvents are those which are promoters of drying and include, for example, absolute ethanol, isopropanol (2-propanol) or methanol.
  • the crystallization inhibitor can in particular be present in a proportion of about 1 to about 20% (W/V), preferably of about 5 to about 15%.
  • the inhibitor preferably corresponds to the test in which 0.3 ml of a solution comprising 10% (W/V) of the compound of formula (I) in the liquid carrier and 10% of the inhibitor are deposited on a glass slide at 20° C. and allowed to stand for 24 hours. The slide is then observed with the naked eye.
  • Acceptable inhibitors are those whose addition provides for few or no crystals, and in particular less than 10 crystals, preferably 0 crystals.
  • the formulation can optionally comprise water, in particular in a proportion of 0 to about 30% (volume by volume V/V), in particular of 0 to about 5%, although this is not always preferred.
  • the formulation can also comprise an antioxidizing agent intended to inhibit oxidation in air, this agent being particularly present in a proportion of about 0.005 to about 1% (W/V), preferably of about 0.01 to about 0.05%.
  • Crystallization inhibitors which may be included in the spot-on or pour-on formulation.
  • Non-limiting examples of crystallization inhibitors include:
  • a crystallization inhibitor pair will be used.
  • Such pairs include, for example, the combination of a film-forming agent of polymeric type and of a surface-active agent. These agents will be selected in particular from the compounds mentioned above as crystallization inhibitors.
  • Particularly preferred film-forming agents of polymeric type include:
  • Especially preferred surface-active agents include those made of non-ionic surfactants, preferably polyoxyethylenated esters of sorbitan and in particular the various grades of polysorbate, for example Polysorbate 80.
  • the film-forming agent and the surface-active agent can in particular be incorporated in similar or identical amounts within the limit of the total amounts of crystallization inhibitor mentioned elsewhere.
  • the pair thus constituted secures, in a noteworthy way, the objectives of absence of crystallization on the coat and of maintenance of the cosmetic appearance of the fur, that is to say without a tendency towards sticking or towards a sticky appearance, despite the high concentration of active material.
  • antioxidizing agents are those conventional in the art and include, for example, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate, sodium thiosulphate or a mixture of not more than two of them.
  • composition adjuvants discussed above are well known to the practitioner in this art and may be obtained commercially or through known techniques. These concentrated compositions are generally prepared by simple mixing of the constituents as defined above; advantageously, the starting point is to mix the active material in the main solvent and then the other ingredients or adjuvants are added.
  • the amount of 1-N-arylpyrazole for birds and animals which are small in size is preferably greater than about 0.01 mg and in a particularly preferred way between about 1 and about 50 mg/kg of weight of animal.
  • the amount of 1-N-arylpyrazole for topical combinations comprising 1-N-arylpyrazoles and IGR's it is preferable to administer to the animal a dose of from about 0.1 to about 40 and in particular from about 1 to about 20 mg/kg of 1-N-phenylpyrazole and a dose of from about 0.1 to about 40 and in particular about 1 to about 30 mg/kg of IGR compound.
  • Preferred doses are from about 5 to about 15 mg/kg of 1-N-arylpyrazoles and from about 0.5 to about 15 mg/kg for the preferred IGR compounds, or about 10 to about 20 mg/kg for the other IGR compounds.
  • the liquid carrier vehicle comprises a pharmaceutically or veterinary acceptable organic solvent and optionally an organic cosolvent.
  • the volume applied can be of the order of about 0.3 to about 1 ml, preferably of the order of about 0.5 ml, for cats and of the order of about 0.3 to about 3 ml for dogs, depending on the weight of the animal.
  • nodulisporic acid derivatives generally a dose of from about 0.001 to about 100 mg per kg of body weight, with a range of 0.25 to 50 mg/kg being especially preferred, given as a single dose or in divided doses for a period of from about 1 to about 60 days, preferably from about 1 to 30 days.
  • Preferred amounts of anthelmintic agents such as praziquantel or morantel include, for example, from about 0.5 mg/kg to about 7.5 mg/kg of animal body weight, with a range of about 0.5 mg/kg to about 2 mg/kg or 2.5 mg/kg of body weight being especially preferred. A most especially preferred amount is about 1.0 mg/kg of animal body weight.
  • Preferred ranges for the macrolide compounds include, for example about 0.01 to about 200 mg/kg of animal body weight, with the ranges of about 0.1 to about 50 mg/kg and from about 1 to about 30 mg/kg being especially preferred.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A liquid agent applicator including a collapsible reservoir for storing the liquid agent, and a shaft having a lumen there through connected to the collapsible reservoir. The liquid agent applicator also includes an opening mechanism that is inserted into an orifice in one end of said shaft. The liquid agent applicator being sealed by a breakable seal formed between the opening mechanism and the shaft, wherein twisting of the opening mechanism relative to the shaft breaks the seal allowing egress of the liquid agent stored in the reservoir.

Description

    INCORPORATION BY REFERENCE
  • Each document cited in this text (“application cited documents”) and each document cited or referenced in each of the application cited documents, and any manufacturer's specifications or instructions for any products mentioned in this text and in any document incorporated into this text, are hereby incorporated herein by reference; and, technology in each of the documents incorporated herein by reference can be used in the practice of this invention. In addition, commonly assigned design patent application of PATRICE WURTZ and SUSAN LIEBENGUTH concurrently filed herewith titled “PIPETTE/APPLICATOR and OPTIONAL TOPS THEREFOR” (Attorney Docket No. MER 04-030) is hereby incorporated by reference.
  • It is noted that in this disclosure, terms such as “comprises”, “comprised”, “comprising”, “contains”, “containing” and the like can have the meaning attributed to them in U.S. patent law; e.g., they can mean “includes”, “included”, “including” and the like. Terms such as “consisting essentially of” and “consists essentially of ” have the meaning attributed to them in U.S. patent law, e.g., they allow for the inclusion of additional ingredients or steps that do not detract from the novel or basic characteristics of the invention, i.e., they exclude additional unrecited ingredients or steps that detract from novel or basic characteristics of the invention, and they exclude ingredients or steps of the prior art, such as documents in the art that are cited herein or are incorporated by reference herein, especially as it is a goal of this document to define embodiments that are patentable, e.g., novel, nonobvious, inventive, over the prior art, e.g., over documents cited herein or incorporated by reference herein. And, the terms “consists of” and “consisting of” have the meaning ascribed to them in U.S. patent law; namely, that these terms are closed ended.
    • FIELD OF THE INVENTION
  • The present invention is directed to a new and useful apparatus for dispensing liquid agents. Specifically, the present invention is directed to an apparatus for applying liquids to the skin of an animal for the prevention and treatment of disease or parasite infestation.
    • BACKGROUND OF THE INVENTION
  • There are known in the prior art a variety of devices for the application of liquids onto the skin of animals. One well known device is a syringe. A syringe includes a body in which the liquid is stored, a plunger that forces the liquid out of the body, and a needle or applicator tip for accurately locating the point of application of the liquid. While such a device is well suited for injection of liquids into the body, it is not well suited for topical application. One obvious drawback of this device in the topical application situation is the apparent danger of puncturing the skin of the animal or the person applying the liquid when using a syringe with a needle. Many liquid agents, which are intended for topical use can have harmful or irritating reactions when applied beneath the skin of the animal. For at least this reason, the use of syringes is best left to the trained professional, particularly when one considers the strength and agility of an animal such as a large dog and its desire to flee. In addition, although having a seemingly small cost, these devices in fact quite expensive in comparison to other alternative topical application devices. Accordingly, they are not a good alternative for use in inexpensive single use applications.
  • Another device, which has come into some prominence lately, particularly in the application of topical flea and tick preventative agents, is a type of plastic pipette. One common device 50, shown in FIG. 2, comprises a storage chamber 52 formed of a flexible plastic material 56 and a semi or substantially rigid material 54. The device further comprises, a narrowed neck 58, and a break away tip 60. Flexible materials typically have a thickness below about 100 μm and include for example polyesters, polyamides, polypropylenes, polyolefins, and aluminum foils. Preferably, the aluminium foils have a thickness of less than about 20 μm. Rigid materials typically have a thickness of below about 200 μm and include for example, polyethylene terephthalate (PET), amorphous polyethylene terephthalate (APET), polyethylene terephthalate glycol (PETG), or crystalline polyethylene terephthalate (CPET), polyvinyl chloride (PVC), polypropylene (PP), cycloolefin copolymers such as that known under the tradename COC®, poly acrilo nitrile (PAN) such as that known under the tradename BAREX®, fluropolymer or chlorotrifluoroetheylene (CTFE) such as that known under the tradename ACLAR®, and aluminum foils up to about 100 μm. In use, the tip 60 of the pipette 50 is broken off to allow for the free flow of the liquid agent from the storage chamber 52 to the skin of the animal via the neck 58. Once the tip 60 is broken off, the pipette 50 is arranged on the animal so that the neck 58 of the pipette parts the animals hair, and the storage chamber 52 is squeezed to compress the flexible material 56 against the rigid material 54 and force the liquid agent through the neck 58, and onto the skin of the animal.
  • This device, however, has several drawbacks. The first of these is that the break away tip 60 can be difficult to break due to the use of the rigid materials discussed above. A struggle with the tip, by the user, can sometimes result in the undesirable release of the liquid agent onto the user. Many of the agents, particularly anti-flea and tick agents, can be very irritating when inadvertently applied to human skin, and pose an even greater danger if inadvertently splashed into the eyes or mouth of the user. In addition, these break away tips typically require the use of two hands to open before the user can apply the liquid to the animal.
  • In addition, because of the use of separate materials, (e.g. flexible and rigid) further difficulties are created. One of these is that the tip 60 may remain attached to the pipette 50 after breaking. This can lead to an inability for the user to penetrate the animal's fur after opening. Naturally, since these medications are to be absorbed through the skin, the failure to apply them directly onto the skin poses dosing problems.
  • Yet another drawback, of the prior art device, is that when the tip is broken off, a sharp edge may be formed on the end of the neck by the severed end of the rigid material 54. This edge can be sharp enough to injure either the animal or the user. Application of the liquid agent to an animal or user that has been cut by the sharp edge can be very irritating.
  • Accordingly, there is a need for a liquid agent applicator that is easy to open without potential for spraying the user, that ensures the liquid agent application to the skin and beneath the hair of the animal, and that does not retain a sharp edge after opening.
    • SUMMARY OF THE INVENTION
  • It is one advantageous embodiment of the present invention to produce a liquid agent applicator that is safe for both the user and an animal receiving treatment.
  • It is another advantageous embodiment of the present invention produce a liquid agent applicator that can be opened by a user single-handedly, does not have a likelihood of splashing the user with the liquid agent, and does not produce a sharp edge upon opening.
  • It is yet another advantageous embodiment of the present invention to produce a liquid agent applicator that can be placed in an upright position after opening.
  • It is yet another advantageous embodiment of the present invention to produce a liquid agent applicator that is child resistant.
  • Accordingly, a liquid agent applicator is described having a collapsible reservoir for storing the liquid agent and a shaft having a lumen there through connected to the collapsible reservoir. The liquid agent applicator includes an opening mechanism inserted into an orifice formed in one end of the shaft and a breakable seal formed between the opening mechanism and the shaft. Further, twisting of the opening mechanism relative to the shaft breaks the seal allowing egress of the liquid agent stored in the reservoir.
  • In another embodiment, the liquid applicator includes a child resistant opening mechanism. The child resistant opening mechanism includes a rigid stationary neck and a movable cap. The child resistant opening mechanism also includes a septum for preventing the egress of liquid from the reservoir formed on the stationary neck, and a punch formed on the movable cap, for piercing the septum to allow the egress of liquid from the reservoir. The child resistant opening mechanism also includes an interlock requiring two or more movements of the movable cap by the user, wherein upon completion of the two or more actions, the movable cap is movable along the stationary neck in the direction of the septum. And movement of the stationary cover in the direction of the septum causes the punch to pierce the septum and release the liquid agent.
  • These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The following Detailed Description, given to describe the invention by way of example, but not intended to limit the invention to specific embodiments described, may be understood in conjunction with the accompanying Figures, incorporated herein by reference, in which:
  • FIG. 1 is a perspective view of a liquid applicator according to the present invention;
  • FIG. 2 a is a front view of a prior art pipette;
  • FIG. 2 b is a side view of a prior art pipette;
  • FIG. 3 a is a cross-sectional view of a shaft of a pipette according to one embodiment of the present invention;
  • FIG. 3 b is a cross sectional view of a shaft of a pipette according to another embodiment of the present invention.
  • FIG. 4 is a cross-sectional view of a CR shaft according to one embodiment of the present invention; and
  • FIG. 5 is side view of a CR shaft according to one embodiment of the present invention.
  • FIG. 6 is a perspective view of a liquid applicator with a CR shaft.
  • FIG. 7 is a perspective view of three examples of one embodiment of the present invention as formed by a thermoforming process.
  • FIG. 8 is a front view of three examples of one embodiment of the present invention as formed by a thermoforming process.
    • DETAILED DESCRIPTION
  • A pipette according to the present invention is shown if FIG. 1. As can be seen by reference to FIG. 1, the pipette 10 includes a base or reservoir 12, connected to a shaft 14, and an opening mechanism 16. The shaft 14 has a lumen 24 extending there through fluidly connected to the reservoir 12. The pipette 10 is designed for easy, no-mess, one-handed use.
  • The base or reservoir 12 is advantageously formed with finger grips or notches 18 formed therein to assist the user in grasping the pipette 10. These grips 18 allow the pipette to be held by the user with only two fingers, and further enable the user to apply pressure to the reservoir 12, of the pipette 10, for application of the liquid stored therein using just these two fingers. Accordingly, the grips 18 assist the user by providing means for safe and effective one handed holding and use of the pipette 10.
  • The reservoir 12 is advantageously shaped with a substantially flat or slightly concave bottom 20, which enables the pipette 10 to be placed in an upright position on a flat surface such as a table or counter. The bottom 20 represents a considerable advantage to the user in that he/she can open the pipette 10 and place it down without fear that the contents of the pipette will spill out. Particularly in use with animals and more particularly in the application of anti-flea and tick liquids such a feature is particularly useful. Often after opening a pipette there may be reason for the pipette to be place down on a table or counter. These reasons can include the need to reposition the animal or the user's grip on the animal, or simply being finished with application before disposal of the pipette. Previously known pipettes used for such applications were formed with a base that did not allow for upright placement of the pipette, as shown in FIG. 2. Accordingly, any post-opening placement of the pipette on a flat surface was likely to result in spillage of the liquid contained therein. As many of these liquids can cause reactions when they come in contact with human skin the prevention of such a spillage represents a substantial benefit to the user.
  • The reservoir 12 is formed of a collapsible material that allows the user to apply pressure to the finger grips with just two fingers of one hand and force the fluid contained in the reservoir through the shaft 14. However, in one advantageous embodiment, the reservoir 12 is formed of a material having sufficient rigidity that initial grasping of the reservoir 12 by the user will not compress the reservoir 12 sufficiently to cause the liquid agent to be expelled from the orifice of the shaft 14. To propel the liquid agent from the reservoir 12 through the shaft 14 and out the orifice, requires an appreciable but not undue amount of force in excess of that required to grasp and hold the pipette 10. One of skill in the art will understand that a variety of suitable plastic materials may be used to form the pipette 10. Further these plastic materials may be formed as a single or monolayer, alternatively the plastic materials may be formed as a lamination of multiple plastic layers without departing from the scope of the present invention.
  • Another feature of the pipette 10 that aids in the ease of one-handed use is the opening mechanism 16, as shown in FIG. 3. The opening mechanism 16 is formed so that twisting will remove it from the shaft 14. In one embodiment, the opening mechanism 16 may be threaded like a bolt into the lumen 24 of the shaft 14. In this embodiment, threads are formed on both the interior of the shaft, and the exterior of a plug 30 of the opening mechanism 16. Alternatively, the plug 30 may simply be inserted into the orifice formed at the end of the lumen 24 in the shaft 14 with sufficient force to prevent express of the fluid without removal of the plug. Twisting of the opening mechanism 16 allows the user to extract the plug 30 from the lumen 24.
  • In a further embodiment shown in FIG. 3 b, a plastic seal 25 can be formed between the plug 30 and the shaft 14, preventing the egress of liquid out of the pipette 10. The seal 25 maybe formed, for example, of a narrowed thickness of plastic material. The plastic material of the seal 25 may be formed so that twisting of the opening mechanism 16 will overcome the tensile strength of the material causing it to shear, thereby breaking the seal. Once the seal 25 is broken, the plug 30 can be removed from the shaft 14 and an orifice is created in the shaft 14, which allows for dispensation of the fluid agent from the pipette 10. In one advantageous embodiment, the seal 25 is formed of the same plastic material as the plug 30 and the shaft 14.
  • In any event, opening mechanism 16 is grasped by as few as two of the user's fingers, while the pipette 10 rests in the palm of the user's hand. By application of a rotational force to the opening mechanism 16 by the user's two or more fingers, the pipette 10 is opened one-handed. Enabling one-handed opening of the pipette simplifies the application of fluids such as flea and tick repellants to dogs and cats. One problem with pipettes currently used in such applications, as shown in FIG. 2, is that they, typically require two hands to open. This in turn may require a second person to assist in holding the animal while the user opens the pipette. Alternatively, a user may attempt to hold the animal between their knees while opening the pipette. Particularly with the very large and very small animals this can present dangers to both the animal and the user. Accordingly, by providing a pipette 10 that can be opened with a single hand, the user's second hand is free to hold the animal for application, eliminating the need for a second person and removing many of the dangers to both animal and user that other means of restraint can pose.
  • Another advantage of the twist top opening mechanism 16 is that it prevents the formation of a sharp edge at the tip 22 of the shaft 14. As discussed above, use of many of the prior art devices resulted in the formation of a sharp plastic edge that could injure the animal during application. As many of the topical use liquid agents can be very irritating if administered into the skin of the animal or the user, the likelihood of scratching the skin presents a problem for the user and the animal. In one embodiment discussed above, the sealing of the shaft 14 of the pipette 10 to the plug 30 is accomplished using the plastic materials of the plug 30 and the shaft 14 to form a seal. The seal has a reduced tensile strength in comparison to the plug 30 and the shaft 14 that can be sheared when the opening mechanism 16 is twisted. A further feature of this embodiment is that the seal may be formed in the lumen 24. As can be readily understood, the placement of the seal at the tip 22 of the shaft 14 may not necessarily result in the prevention of a sharp edge forming on the tip 22 upon the removal of the opening mechanism 16 from the shaft 14. Accordingly, by forming the seal between the shaft 14 and the plug 30 of the opening mechanism 16 inside the lumen 24, no sharp edge will be formed on the tip 22. As a result the dangers associated with such a sharp edge are greatly reduced and there is little likelihood of injury to either the user or the animal.
  • The shaft 14 of the pipette 10 is advantageously formed of a substantially rigid material that resists bending. The shaft 14 is also formed with a long neck to assist in proper dosing. The long neck and resistance to bending provide beneficial support for the pipette 10 during application of the fluid agent on the animal. In particular, the stiffness or resistance to bending and the long neck allow the user to easily part the animal's hair or fur for application directly on the animals skin. In one advantageous example of the invention, the shaft 14 is between 1 and 5 cm in length.
  • As discussed previously, one of the major failings of some pipettes of the prior art is that the break away tip 60, as shown in FIGS. 2 a and b, tends to remain connected to the pipette which further frustrates proper dosing. In certain circumstances this could result in the animal receiving insufficient treatment and thereby compromise the effectiveness of the treatment regimen. Accordingly, the present invention provides for superior application and greater guarantees of proper dosing of the animal. One skilled in the art will readily appreciate that a variety of materials could be used to produce a shaft 14 having the proper stiffness and flexibility as described above, accordingly such materials are considered within the scope of the present invention.
  • Another embodiment of the present invention is a child resistant or CR shaft 44, for use with the pipette 10. The CR shaft 44 includes a rigid stationary neck 45, a movable cap 48, and a septum 46. The septum 46 acts as a seal on the pipette 10 preventing the egress of a liquid agent contained therein. The movable cap 48 includes a punch 49. The punch 49 includes a piercing tip of sufficient rigidity to allow the punch 49 to pierce the septum 46. The piercing of the septum 46 allows for the free flow of the liquid agent from the reservoir 12 of the pipette 10 to the CR shaft, 44. After piercing of the septum 46, the cap 48 is removed and the liquid is able to flow from the pipette 10. The CR shaft 44 also includes a means for preventing a child from opening the pipette 10. This means for preventing a child from opening the pipette 10 may be of a type know in the art. For example, the prevention means can include requiring depression or extension of the movable cap 48 vertically to a first position and twisting of the cover while in this first position to a rotational stop point. Once the rotational stop point is reached depression of the movable cap 48 allows the punch 49 to pierce the septum 46. After removal of the cap 48 from the CR shaft 44, the piercing of the septum 46 allows fluid communication of the liquid agent in the pipette 10 through the lumen and onto the animal. Other means of preventing a child from opening the pipette 10 will be known to those of skill in the art and are therefore considered within the scope of the present invention.
  • In a further embodiment, the cap 48 may include a lumen (not shown) which extends through the punch 49. This allows for egress of fluid from the pipette 10 after piercing of the septum 46.
  • One method of manufacturing such a pipette 10 is called thermoforming. In the thermoforming process, sheets of a desired plastic material are fed into a press. These sheets may be formed of one or more layers of plastic material. The press contains a mold of the shape to be formed for example, the reservoir 12 of the pipette 10. By heating the plastic sheets, and applying air pressure to the area between the sheets of plastic the reservoir 12 is formed. The air pressure forces a portion of the now heated plastic sheets into the molds to form the shape of the reservoir 12. In addition, the heat acts to seal the two sheets of plastic material together to form a single plastic sheet having a reservoir 12. The heat is removed, and upon cooling, reservoir 12 may be cut from the plastic sheet. FIGS. 7 and 8 show three examples of the present invention formed by a thermoforming process.
  • After formation, the reservoir 12 can then be filled with the desired liquid agent, for example a flea and tick repellant for use with domestic animals such as dogs and cats. After filling, the shaft 14 with opening mechanism 16 is inserted into an opening in the reservoir 12. Further application of heat to the opening in the reservoir 12 acts to seal the reservoir 12 to the shaft 14, thereby creating a sealed pipette 10 which can then be cut from the sheet of plastic for packaging and sale.
  • In other embodiments, the base 12 is formed and the shaft 14 inserted therein. After application of heat to the base 12 and shaft 14 combination, the liquid agent is added via an orifice in the end of the shaft 14. After filling the opening mechanism 16 is inserted into the orifice. Application of yet another source of heat seals the opening mechanism 16 to the shaft 14.
  • Formulations for Use with the Applicator
  • Any liquid agent may be stored and administered to the animal or human by this applicator. Preferred liquid agents are topical pharmaceutical or veterinary formulations. Therapeutic agents, which are present in the formulations, include, for example, substances or combination of substance such as, for example, antiviral, antibacterial, antiparasitic, antifungal substances and combinations thereof. The therapeutic agent may further be a substance, capable of acting as a stimulant, sedative, hypnotic, analgesic, anticonvulsant, and the like. Examples of these therapeutic agents include, but are not limited to: Anti-inflammatory agents such as hydrocortisone, prednisone, fludrotisone, triamcinolone, dexamethasone, betamethasone and the like. Anti-bacterial agents such as penicillins, cephalosporins, vancomycin, bacitracin, polymycins, tetracyclines, chloramphenicol, erythromycin, streptomycin, and the like. Antiparasitic agents such, as quinacrine, chloroquine, quinine, and the like. Antifungal agents such as nystatin, gentamicin, miconazole, tolnaftate, undecyclic acid and its salts, and the like. Antiviral agents such as vidarabine, acyclovir, ribarivin, amantadine hydrochloride, iododeoxyuridine, dideoxyuridine, interferons and the like. Antineoplastic agents such as methotrexate, 5-fluorouracil, bleomycin, tumor necrosis factor, tumor specific antibodies conjugated to toxins, and the like. Analgesic agents such as salicylic acid, salicylate esters and salts, acetaminophen, ibuprofen, morphine, phenylbutazone, indomethacin, sulindac, tolmetin, zomepirac, and the like. Local anaesthetics such as cocaine, benzocaine, novocaine, lidocaine, and the like. Vaccines, or antigens, epitopes, immunogens of human or animal pathogens, such as hepatitis, influenza, measles, mumps, rubella, hemophilus, diphtheria, tetanus, rabies, polio, as well as veterinary vaccines and the like. Central nervous system agents such as tranquilizers, sedatives, anti-depressants, hypnotics, β-adrenergic blocking agents, dopamine, and the like. Growth factors such as colony stimulating factor, epidermal growth factor, erythropoietin, fibroblast growth factor, neural growth factor, human growth hormone, platelet derived growth factor, insulin-like growth factor, and the like. Hormones such as progesterone, estrogen, testosterone, follicle stimulating hormone, chorionic gonadotrophin, insulin, endorphins, somatotropins and the like. Antihistamines such as diphenhydramine, chlorpheneramine, chlorcyclizine, promethazine, cimetidine, terfenadine, and the like. Cardiovascular agents such as verapamil hydrochloride, digitalis, streptokinase, nitroglycerine paparefine, disopyramide phosphate, isosorbide dinitrate, and the like. Anti-ulcer agents such as cimetidine hydrochloride, sopropamide iodide, propantheline bromide, and the like. Bronchodilators such as metaproternal sulfate, aminophylline, albuterol, and the like. Vasodilators such as theophylline, niacin, nicotinate esters, amylnitrate, minoxidil, diazoxide, nifedipine, and the like.
  • The therapeutic agents which are used in the formulations for the inventive applicator can be well known to the practitioner to which this invention pertains. Classes of therapeutic agents contemplated by the inventive formulations include insecticides, acaricides, parasiticides, growth enhancers, and oil-soluble, nonsteroidal anti-inflammatory drugs (NSAIDs). Specific classes of compounds which fall within these classes include, for example, avermectins, milbemycins, nodulisporic acid and its derivatives, estrogens, progestins, androgens, substituted pyridylmethyl derivatives, phenylpyrazoles, and COX-2 inhibitors.
  • The avermectin and milbemycin series of compounds are potent anthelmintic and antiparasitic agents against a wide range of internal and external parasites. The compounds which belong to this series are either natural products or are semi-synthetic derivatives thereof. The structure of these two series of compounds are closely related and they both share a complex 16-membered macrocyclic lactone ring; however, the milbemycin do not contain the aglycone substitutent in the 13-position of the lactone ring. The natural product avermectins are disclosed in U.S. Pat. No. 4,310,519 to Albers-Schonberg, et al., and the 22,23-dihydro avermectin compounds are disclosed in Chabala, et al., U.S. Pat. No. 4,199,569. For a general discussion of avermectins, which include a discussion of their uses in humans and animals, see “Ivermectin and Abamectin,” W. C. Campbell, e d., Springer-Verlag, New York (1989). Furthermore, bioactive agents such as avermectins or ivermectin can be used in combination with other bioactive agents; and, with respect to a vermectins, ivermectin, and bioactive agent combinations, reference is made to Kitano, U.S. Pat. No. 4,468,390, Beuvry et al., U.S. Pat. No. 5,824,653, von Bittera et al., U.S. Pat. No. 4,283,400, European Patent Application 0 007 812 A1, published June 2, 1980, U.K. Patent Specification 1 390 336, published Apr. 9, 1975, European Patent Application 0 002 916 A2, Ancare New Zealand Patent No. 237 086, Bayer New Zealand Patent 176193, published Nov. 19, 1975, inter alia.
  • Naturally occurring milbemycins are described in Aoki et al., U.S. Pat. No. 3,950,360 as well as in the various references cited in “The Merck Index” 12th ed., S. Budavari, Ed., Merck & Co., Inc. Whitehouse Station, N.J. (1996). Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in U.S. Pat. No. 5,077,308, U.S. Pat. No. 4,859,657, U.S. Pat. No. 4,963,582, U.S. Pat. No. 4,855,317, U.S. Pat. No. 4,871,719, U.S. Pat. No. 4,874,749, U.S. Pat. No. 4,427,663, U.S. Pat. No. 4,310,519, U.S. Pat. No. 4,199,569, U.S. Pat. No. 5,055,596, U.S. Pat. No. 4,973,711, U.S. Pat. No. 4,978,677, and U.S. Pat. No. 4,920,148.
  • Nodulisporic acid and its derivatives are a class of acaricidal, antiparasitic, insecticidal and anthelminitic agents known to a practitioner of the art. These compounds are used to treat or prevent infections in humans and animals. These compounds are described, for example, in U.S. Pat. No. 5,399,582 and WO 96/29073.
  • Especially preferred therapeutic agents include nodulisporic acid compounds A, B, and C as well as nodulisporic acid derivatives of the formula:
    Figure US20060011666A1-20060119-C00001
    wherein
  • R1 is (1) hydrogen,
      • (2) optionally substituted alkyl,
      • (3) optionally substituted alkenyl,
      • (4) optionally substituted alkynyl,
      • (5) optionally substituted cycloalkyl,
      • (6) optionally substituted cycloalkenyl,
      • where the substituents on the alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl are 1 to 3 groups independently selected from
        • (i) alkyl,
        • (ii) alkyl, where X is O or S(O)m.
        • (iii) cycloalkyl,
        • (iv) hydroxy,
        • (v) halogen,
        • (vi) cyano,
        • (vii) carboxy,
        • (viii) NY1Y2, where Y1 and Y2 are
      • independently H or alkyl,
        • (ix) alkanoylamino, and
        • (x) aroylamino wherein said aroyl is optionally substituted with 1 to 3 groups independently selected from Rf
      • (7) aryl or arylalkyl, wherein said aryl is optionally substituted with 1 to 3 groups independently selected from Rf,
      • (8) perfluoroalkyl
      • (9) a 5- or 6-member heterocycle containing from 1 to 4 heteroatoms independently selected from oxygen, sulfur and nitrogen atoms optionally substituted by 1 to 3 groups independently selected from hydroxy, oxo, alkyl and halogen, and which may be saturated or partly unsaturated,
  • R2, R3, and R4 are independently ORa, OCO2Rb, OC(O)NRcRd; or
  • R1 and R2 represent ═O, ═NORa or ═N—NRcRd;
  • R5 and R6 are H; or
  • R5 and R6 together represent —O—;
  • R7 is (1) CHO, or
      • (2) the fragment
        Figure US20060011666A1-20060119-C00002
  • R8 is (1) H,
      • (2) ORa, or
      • (3) NRcRd
  • R9 is (1) H, or
      • (2) ORa;
  • R10 is (1) CN,
      • (2) C(O)ORb,
      • (3) C(O)N(ORb)Rc,
      • (4) C(O)NRcRd,
      • (5) NHC(O)ORb,
      • (6) NHC(O)NRCRd,
      • (7) CH2ORa,
      • (8) CH2OCO2Rb,
      • (9) CH2OC(O)NRcRd,
      • (10) C(O)NRcNRcRd, or
      • (11) C(O)NRcSO2Rb;
      • Figure US20060011666A1-20060119-P00001
        represents a single or a double bond;
  • Ra is (1) hydrogen,
      • (2) optionally substituted alkyl,
      • (3) optionally substituted alkenyl,
      • (4) optionally substituted alkynyl,
      • (5) optionally substituted alkanoyl,
      • (6) optionally substituted alkenoyl,
      • (7) optionally substituted alkynoyl,
      • (8) optionally substituted aroyl,
      • (9) optionally substituted aryl,
      • (10) optionally substituted cycloalkanoyl,
      • (11) optionally substituted cycloalkenoyl,
      • (12) optionally substituted alkylsulfonyl
      • (13) optionally substituted cycloalkyl
      • (14) optionally substituted cycloalkenyl where the substituents on the alkyl, alkenyl, alkynyl, alkanoyl, alkenoyl, alkynoyl, aroyl, aryl, cycloalkanoyl, cycloalkenoyl, alkylsulfonyl, cycloalkyl and cycloalkenyl are from 1 to 10 groups independently selected from hydroxy, alkoxy, cycloalkyl, arylalkoxy, NRgRh, CO2Rb, CONRcRd and halogen,
      • (15) perfluoroalkyl,
      • (16) arylsulfonyl optionally substituted with 1 to 3 groups independently selected from alkyl, perfluoroalkyl, nitro, halogen and cyano,
      • (17) a 5- or 6-member heterocycle containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen optionally substituted by 1 to 4 groups independently selected from alkyl, alkenyl, perfluoroalkyl, amino, C(O)NRcRd, cyano, CO2Rb and halogen, and which may be saturated or partly unsaturated;
  • Rb is (1) H,
      • (2) optionally substituted aryl,
      • (3) optionally substituted alkyl,
      • (4) optionally substituted alkenyl,
      • (5) optionally substituted alkynyl,
      • (6) optionally substituted cycloalkyl,
      • (7) optionally substituted cycloalkenyl, or
      • (8) optionally substituted
      • heterocycle containing from 1 to 4 heteroatoms independently selected from oxygen, sulfur and nitrogen; where the substituents on the aryl, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycle, or alkynyl are from 1 to 10 groups independently selected from
        • (i) hydroxy,
        • (ii) alkyl,
        • (iii) oxo,
        • (iv) SO2NRgRh,
        • (v) arylalkoxy,
        • (vi) hydroxyalkyl,
        • (vii) alkoxy,
        • (viii) hydroxyalkoxy,
        • (ix) aminoalkoxy,
        • (x) cyano,
        • (xi) mercapto,
        • (xii) alkyl-S(O)m,
        • (xiii) cycloalkyl optionally substituted
        • with 1 to 4 groups independently selected from Re,
        • (xiv) cycloalkenyl,
        • (xv) halogen,
        • (xvi) alkanoyloxy,
        • (xvii) C(O)NRgRh,
        • (xviii) CO2Ri,
        • (xix) formyl,
        • (xx) —NRgRh,
        • (xxi) 5- to 9-member heterocycle, which may be saturated or partially unsaturated, containing from 1 to 4 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1 to 5 groups independently selected from Re,
        • (xxii) optionally substituted aryl, wherein the aryl substituents are 1,2-methylenedioxy or 1 to 5 groups independently selected from Re,
        • (xxiii) optionally substituted arylalkoxy, wherein the aryl substituents are 1,2-methylenedioxy or 1 to 5 groups independently selected from Re, and
        • (xxiv) perfluoroalkyl;
  • Rc and Rd are independently selected from Rb; or
  • Rc and Rd together with the N to which they are attached form a 3- to 10-member ring containing 0 to 2 additional heteroatoms selected from O, S(O)m, and N, optionally substituted with 1 to 3 groups independently selected from Rg, hydroxy, thioxo and oxo;
  • Re is (1) halogen,
      • (2) alkyl,
      • (3) perfluoroalkyl,
      • (4) —S(O)mRi,
      • (5) cyano,
      • (6) nitro,
      • (7) R10(CH2)v-,
      • (8) RiCO2(CH2)v-,
      • (9) RiOCO(CH2)v-,
      • (10) optionally substituted aryl where the substituents are from 1 to 3 of halogen, alkyl, alkoxy, or hydroxy,
      • (11) SO2NRgRh, or
      • (12) amino;
  • Rf is (1) alkyl,
      • (2) X—C1-C4 alkyl, where X is O or S(O)m,
      • (3) alkenyl,
      • (4) alkynyl,
      • (5) perfluoroalkyl,
      • (6) NY1Y2, where Y1 and Y2 are independently H or alkyl,
      • (7) hydroxy,
      • (8) halogen, and
      • (9) alkanoylamino,
  • Rg and Rh are independently
      • (1) hydrogen,
      • (2) alkyl optionally substituted with hydroxy, amino, or CO2Ri
      • (3) aryl optionally substituted with halogen, 1,2-methylenedioxy, alkoxy, alkyl or perfluoroalkyl,
      • (4) arylalkyl, wherein the aryl is optionally substituted with perfluorolkyl or 1,2-methylenedioxy;
      • (5) alkoxycarbonyl,
      • (6) alkanoyl,
      • (7) alkanoylalkyl,
      • (9) aryl alkoxycarbonyl,
      • (10) aminocarbonyl,
      • (11) monoalkylaminocarbonyl
      • (12) dialkylaminocarbonyl; or
  • Rg and Rh together with the N to which they are attached form a 3- to 7-member ring containing 0 to 2 additional heteroatoms selected from O, S(O)m, and N, optionally substituted with 1 to 3 groups independently selected from Re and oxo;
  • Ri is (1) hydrogen,
      • (2) perfluoroalkyl,
      • (3) alkyl,
      • (4) optionally substituted aryl or arylalkyl, where the aryl substituents are from 1 to 3 groups independently selected from halogen, alkyl, alkoxy, and hydroxy;
  • m is 0 to 2; and
  • v is 0 to 3; or
  • a pharmaceutically acceptable salt thereof.
  • Most especially derivatives include compounds of the formula
    Figure US20060011666A1-20060119-C00003
    wherein Rx is selected from the group consisting of: H, CH3, CH2CH3, C(CH3)3, CH2CH2CH3, CH2CH2OH, CH(CO2CH3)OH, CH2CO2CH3, CH2CH(OCH2CH3)2, CH2CH2OCH2CH2OH, CH(CH3)(CH2)3C(CH3)2OH, (CH2)3OH, (CH2)4OH, (CH2)SOH, CH(CH2OH)CH2CH3, NHC(CH3)3, CH2CN, (CH2)6OH, CH2CH(OH)CH3, CH(CH2OH)CH2CH2CH3, CH2CH2SCH3, CH2CH2SCH2CH3, CH2CONH, CH(CH3)(CH2OH)2, CH2CH2NHCH2CH2OH, CH(CH2OH)(CH2)3CH3, CH(CH2OCH3)CH3, (CH2)2SH, (CH2)4NH2, CH2CH2SO2CH3, CH2CH2S(O)CH3, CH(CH(CH3)2)CH2OH, (CH2)3NH2, (CH2)3N(CH2CH3)2, (CH2)3N(CH3)2, OCH2CH3, CH2CH(OH)CH2OH, OCH3, CH2CH2OCH3, CH2CH2NHC(O)CH3, C(CH3)2CH2OH, c-C3H5, c-C6H11, (CH2)3OCH2CH3, CH2CH≡CH2, C(CH2CH3)(CH2OH)2, CH2C═CH, CH2CO2CH2CH3, CH2CH2F, (CH2)3OCH2)11 CH3, CH2CH2N(CH3)2, CH2CH2OCH2CH2NH2, CH2CF3, NHCH2CO2CH2CH3, CH(CH3)CO2CH3, C(CH3)2CH2C(O)CH3, CH(CO2CH2CH3)2, CH2CH3, CH(CH2CH2CH3)CO2CH3, CH2CH2CH2OCH3, C(CH3)2C≡CH, (CH2)4CH3, CH(CH2CH2CH3)2, (CH2)5CH3, CH2CH2CO2H, CH(CH(CH3)2)CO2CH3, OCH2CO2H, CH(CH(CH3)2)CH2OH, CH(CH(CH3)2)CH2OH, CH(CH3)CH2OH, CH(CH3)CH2OH, CH(CH3)2, C(CH3)3, (CH2)CH(CH3)2, CH(CH3)CH2CH3, CH2CH(CH3)OH, (CH2)3CH3, (CH2)2OCH2CH3, 1 -adamantyl, (CH2)8CH3, CH(CH3)CH(CH3)2, (CH2)3NHCH3, (CH2)2N(CH2CH3)2,
    Figure US20060011666A1-20060119-C00004
  • An e specially preferred nodulisporamide derivative is one wherein RX is with t-butyl (or “nodulisporamide).
  • Generally, all classes of such insecticides may be used in this invention. One example of this class include substituted pyridylmethyl derivatives such as imidacloprid. Agents of this class are described, for example, in U.S. Pat. No. 4,742,060 or in EP 892,060.
  • Pyrazoles such as phenylpyrazoles and N-arylpyrazoles are another class of insecticides which possess excellent insecticidal activity against all insect pests including blood-sucking pests such as ticks, fleas etc., which are parasites on animals. This class of agents kills insects by acting on the gamma-butyric acid receptor of invertebrates. Such agents are described, for example, in U.S. Pat. No. 5,567,429, U.S. Pat. No. 5,122,530, EP 295,117, and EP 846686 A1 (or Banks GB 9625045, filed Nov. 30, 1996 also believed to be equivalent to U.S. Ser. No. 309,229, filed Nov. 17, 1997). It would be well within the skill level of the practitioner to decide which individual compounds can be used in the inventive formulations.
  • Another advantageous formulation for use with the applicator of the present invention comprises:
  • an effective amount of at least one compound of the formula:
    Figure US20060011666A1-20060119-C00005
    in which:
      • R1 is a halogen atom, CN or alkyl;
      • R2 is S(O)nR3 or 4,5-dicyanoimidazol-2-yl or haloalkyl;
      • R3 is alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl or haloalkyl;
      • R4 is hydrogen, halogen, NR5R6, S(O)mR7, C(O)R7, C(O)OR7, alkyl, haloalkyl, OR8 or —N═C(R9)(R10) substituent;
      • R5 and R6 independently represent a hydrogen atom, alkyl, haloalkyl, C(O)alkyl, S(O)rCF3 or alkoxycarbonyl or R5 and R6 together may combine to form a ring of 5 to 7 members.
      • R7 represents an alkyl or haloalkyl group;
      • R8 represents an alkyl, haloalkyl or a hydrogen;
      • R9 represents an alkyl or a hydrogen;
      • R10 represents an optionally substituted aryl or an optionally substituted heteroaryl group;
      • R11 and R12 represent, independently of one another, hydrogen, halogen CN or NO2;
      • R13 represents a halogen atom or a haloalkyl, haloalkoxy, S(O)qCF3 or SF5 group;
      • m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2;
      • X represents a trivalent nitrogen atom or a C—R12, the three other valencies of the carbon atom forming part of the aromatic ring;
      • optionally with a pharmaceutically acceptable carrier or excipient.
  • Another preferred 1-N-arylpyrazole derivative is a compound wherein the ring formed by the divalent alkylene substituent representing R5 and R6 and the nitrogen atom to which R5 and R6 are attached has 5, 6 or 7 members or wherein R1 is CN, R3 is C1-C6-haloalkyl, R4 is NH2, R11 and R12 are, independently of one another, hydrogen or halogen and R13 is C1-C6-haloalkyl.
  • Other 1-N-arylpyrazole derivatives to be used in the formulations that may be administered by the inventive device are those of the formula (II)
    Figure US20060011666A1-20060119-C00006
    wherein:
      • R101 is cyano, —C(O)alkyl, C(S)NH2, alkyl, haloalkyl, C(═NOH)NH2 or C(═NNH2)NH2;
      • R102 is S(O)n′R103, alkenyl, haloalkenyl, cycloalkyl, halocycloalkyl or alkynyl;
      • R103 is alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl or haloalkynyl;
      • R104 is —N═C(R105)-Z-R106, —N═C(R105)—N(R107)—R108; or —N(R109)—C(R105)═NR106;
      • R105 is hydrogen; alkyl; or alkyl substituted by halogen, alkoxy, haloalkoxy or —S(O)m′R105;
      • R106 and R107 each independently represent hydrogen, alkyl, alkenyl or alkynyl, or alkyl substituted by one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or
      • S(O)m′R115; or alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl group; or
      • R107 and R108 may form together with the nitrogen to which they are attached a 3- to 7-membered ring which may additionally contain one or more heteroatoms selected from oxygen, nitrogen or sulfur;
      • R108 is alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, —C(O)R114 or —S(O)t′R110;
      • R109, R110 and R114 are alkyl or haloalkyl;
      • R111 and R112 are independently selected from halogen, hydrogen, CN and NO2
      • R113 is selected from halogen, haloalkyl, haloalkoxy, —S(O)q′CF3, and —SF5;
      • R115 is alkyl or haloalkyl;
      • X is selected from nitrogen and C—R112;
      • Z is O, S(O)a′; or NR107;
      • a′, m′, n′ and q′ are independently selected from 0, 1, and 2; and
      • t′ is 0, 1 or 2; and veterinarily acceptable salts thereof.
  • Another 1-N-arylpyrazole derivatives to be used in topical formulations that may be administered by the present invention are those compounds of formula (III):
    Figure US20060011666A1-20060119-C00007
    wherein:
      • R201 is cyano, C(O)alkyl, C(S)NH2, alkyl, C(═NOH)NH2 or C(═NNH2)NH2;
      • R202 is S(O)hR203, alkenyl, haloalkenyl, cycloalkyl, halocycloalkyl or alkynyl;
      • R203 is alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl or haloalkynyl;
      • R204 is —N(R205)C(O)CR206R207R208, —N(R205)C(O)aryl, or —N(R205)C(O)OR207;
      • R205 is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, cycloalkylalkyl, halocycloalkylalkyl, alkoxyalkyl, haloalkoxyalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl;
      • R206 is hydrogen, halogen, alkoxy, haloalkoxy, alkoxyalkyl, haloalkoxyalkyl, formyloxy, alkylcarbonyloxy, haloalkylcarbonyloxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylamino, dialkylamino, haloalkylamino, di(haloalkyl)amino, cycloalkyloxy, halocycloalkyloxy, alkoxyalkoxy, haloalkoxyalkoxy, alkoxyalkoxyalkoxy, aryloxy, or arylalkoxy;
      • R207 and R208 are independently hydrogen, alkyl, haloalkyl, cycloalkyl, or halocycloalkyl; or R207 and R208 may form together with the carbon to which they are attached a 3- to 7-membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;
      • X1 is selected from nitrogen and C—R212;
      • R211 and R212 are independently selected from halogen, hydrogen, CN and NO2;
      • R213 is selected from halogen, haloalkyl, haloalkoxy, —S(O)kCF3, and —SF5;
      • and
      • h and k are independently selected from 0, 1, and 2;
      • and veterinarily acceptable carrier, excipients and salts thereof
  • Another group of 1-N-arylpyrazole derivatives are 4-thiocarbonylpyrazole derivatives of the formula:
    Figure US20060011666A1-20060119-C00008
    in which
      • R301 is H2N—C(S)—,
      • R302 is halogenoalkyl, halogenoalkenyl or halogenoalkynyl,
      • R303 is hydrogen, amino or one of the following groups:
        Figure US20060011666A1-20060119-C00009
        where
      • R304 represents alkyl, halogenoalkyl, alkoxyalkyl or in each case optionally substituted phenyl or pyridyl,
      • R305 represents hydrogen or alkyl,
      • R306 represents hydrogen, alkyl or in each case optionally substituted phenyl or pyridyl and
      • R307 represents alkyl, alkenyl, alkinyl, formyl, alkylcarbonyl, halogenoalkylcarbonyl or alkoxycarbonyl;
      • Ar represents in each case optionally substituted phenyl or pyridyl and n represents a number 0, 1 or 2.
  • Additional derivatives of formula (IV) are those wherein
      • R301 represents H2N—C(S)—;
      • R302 preferably represents (C1-C6)-halogenoalkyl having 1 to 12 halogen atoms; (C2-C6)-halogenoalkenyl having 1 to 8 halogen atoms or (C1-C6)-halogenoalkinyl having 1 to 6 halogen atoms;
      • R303 preferably represents hydrogen, amino or one of the following groups:
        Figure US20060011666A1-20060119-C00010
        wherein:
      • R304 represents (C1-C6)-alkyl, (C1-C6)-halogenoalkyl having 1 to 3 halogen atoms, (C1-C6)-alkoxy-(C1-C6)-alkyl, or represents phenyl or pyridyl, each of which is optionally monosubstituted to trisubstituted by identical or different substituents from the group consisting of cyano, nitro, halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C4-halogenoalkyl, C1-C4 halogenoalkoxy or C1-C4-halogenoalkylthio having in each case 1 to 5 halogen atoms,
      • R305 represents hydrogen or (C1-C6)-alkyl,
      • R306 represents hydrogen, (C1-C6)-alkyl, phenyl which is optionally monosubstituted to trisubstituted by identical or different substituents from the group consisting of cyano, nitro, halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C4-halogenoalkyl, C1-C4-halogenoalkoxy or C1-C4-halogenoalkylthio having in each case 1 to 5 halogen atoms or hydroxyl, or represents pyridyl which is substituted by cyano, nitro, halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylthio, C1-C4-halogenoalkyl, C1-C4-halogenoalkoxy or C1-C4-halogenoalkylthio having in each case 1 to 5 halogen atoms, and
      • R307 represents (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, formyl, (C1-C6)-alkylcarbonyl, (C1-C6)-halogenoalkylcarbonyl having 1 to 6 halogen atoms or (C1-C6)-alkoxycarbonyl;
      • Ar preferably represents phenyl or pyridyl, each of which is optionally monosubstituted to trisubstituted by identical or different substituents from the group consisting of halogen halogeno(C1-C6)alkyl, halogeno(C1-C6)alkylthio, halogeno(C1-C6)alkoxy, (C1-C6)alkoxy, methoxy, hydrazine, (C1-C6)-dialkylhydrazino, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, (C1-C6)alkylimino, cyano, (C1-C6)alkylthio or the group
        Figure US20060011666A1-20060119-C00011
        in which
      • R308 and R309 are identical or different and represent hydrogen or (C1-C6)-alkyl
      • n111 preferably represents a number 0, 1 or 2;
      • R301 represents H2N—C(S)—;
      • R302 particularly preferably represents (C1-C4)-halogenoalkyl having 1 or 9 identical or different halogen atoms from the group consisting of fluorine, chlorine and bromine, (C2-C4)-halogenoalkenyl having 1 to 5 identical or different halogen atoms from the group consisting of fluorine, chlorine or bromine or (C2-C4)-halogenoalkynyl having 1 to 5 identical or different halogen atoms from the group consisting of fluorine, chlorine and bromine;
      • R303 especially preferably represents hydrogen, amino or one of the following groups:
        Figure US20060011666A1-20060119-C00012
        where
      • R304 represents (C1-C4)-alkyl, (C1-C4)-halogenoalkyl having 1-3 halogen atoms, (C1-C4)-alkoxy(C1-C2)-alkyl, or phenyl which is optionally monosubstituted to trisubstituted by identical or different substituents from the group consisting of hydroxyl, cyano, nitro, halogen, C1-C4-alkyl, C1-C4-alkoxy, (C1-C2-halogenoalkyl, C1-C2-halogenoalkoxy or C1-C2-halogenoalkylthio having in each case 1 to 3 halogen atoms,
      • R305 represents hydrogen or (C1-C4)-alkyl,
      • R306 represents hydrogen, (C1-C4)-alkyl or phenyl which is optionally monosubstituted or disubstituted by identical or different substituents from the group consisting of hydroxyl, cyano, nitro, halogen, C1-C4-alkyl, C1-C4-alkoxy, C1-C2-halogenoalkyl, C1-C2 halogenoalkoxy or C1-C2 halogenoalkylthio having in each case 1 to 3 halogen atoms, in particular 4-hydroxy-3-methoxy-phenyl, and
      • R307 represents (C1-C4)-alkyl, (C2-C4)-alkenyl, (C2-C4)-alkynyl, formyl, (C1-C4)-alkylcarbonyl, (C1-C4,)-halogenoalkylcarbonyl having 1 to 5 identical or different halogen atoms from the group consisting of fluorine, chlorine or bromine or (C1-C4)-alkoxycarbonyl;
      • Ar especially preferably represents phenyl or pyridyl, each of which is optionally monosubstituted to trisubstituted by identical or different substituents from the group consisting of fluorine, chlorine, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methoxy, hydrazine, dimethylhydrazino, amino, methylamino, dimethylamino, iminomethyl, cyano, methylthio or the group
        Figure US20060011666A1-20060119-C00013
        where
      • R308 and R309 are identical or different and represent hydrogen or (C1-C4)-alkyl;
      • n111 especially preferably represents a number 0, 1 or 2.
  • The alkyl groups of the definition of the compounds (1) of the formula (I) generally comprise from 1 to 6 carbon atoms. The ring formed by R5 and R6 and the nitrogen atom to which they are attached is generally a 5-, 6- or 7-membered ring.
  • Unless otherwise specified, alkyl and alkoxy groups are generally lower alkyl and alkoxy groups, that is having from one to six carbon atoms, preferably from one to four carbon atoms. Generally, the haloalkyl, haloalkoxy and alkylamino groups have from one to four carbon atoms. The haloalkyl and haloalkoxy groups can bear one or more halogen atoms; preferred groups of this type include —CF3 and —OCF3. Cycloalkyl groups generally have from 3 to 6 carbon atoms, preferably from 3 to 5 carbon atoms, and may be substituted by one or more halogen atoms. Alkenyl, haloalkenyl, alkynyl, and haloalkynyl groups generally contain from 3 to 5 carbon atoms. By the term aryl is generally meant phenyl, pyridyl, furyl, and thiophenyl, each of which is optionally substituted by one or more halogen, alkyl, haloalkyl, nitro, alkoxy, haloalkoxy, hydroxy, amino, alkylamino or dialkylamino. In compounds of formulae (I) to (IV), by the term substituted alkyl is meant alkyl which is substituted by, for example, one or more halogen, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, cyano or —S(O)mR115; or alkyl substituted by phenyl or pyridyl each of which is optionally substituted with one or more groups selected from halogen, nitro and alkyl; wherein R115 is alkyl or haloalkyl and m is zero, one or two. Preferably in compounds of formula (I), alkyl groups are generally substituted by from one to five halogen atoms, preferably from one to three halogen atoms. Chlorine and fluorine atoms are preferred.
  • Compounds of formula wherein R104 is —N═C(R105)-Z-R106, Z is NR107 and R106 represent a hydrogen atom may exist as the tautomeric double bond isomer form —NH—C(R105)═N—R107. It is to be understood that both such forms are embraced by the present invention.
  • In compounds of formula (III) the following examples of substituents are provided:
  • An example of cycloalkylalkyl is cyclopropylmethyl; an example of cycloalkoxy is cyclopropyloxy;
      • An example of alkoxyalkyl is CH3OCH2—;
      • An example of alkoxyalkoxy is CH3OCH2O—;
      • An example of alkoxyalkoxyalkoxy is CH3OCH2OCH2O—;
      • An example of aryloxy is the phenoxy group; and
      • An example of the arylalkoxy group is benzyloxy or 2-phenylethoxy.
  • Generally, in dialkylamino or di(haloalkyl)amino groups, the alkyl and haloalkyl groups on nitrogen may be chosen independently of one another.
  • A preferred class of compounds of formula (I) comprises the compounds such that R1 is CN, R3 is haloalkyl, R4 is NH2, R11 and R12 are, independently of one another, a halogen atom and R13 is haloalkyl. Preferably still, X is C—R12. A compound of formula (I) which is very particularly preferred in the invention is 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole or fipronil.
  • Compounds of formulae (I)-(III) can be prepared according to one or other of the processes described in Patent Applications WO 87/3781, 93/6089 and 94/21606, and 00/59862 or European Patent Application 295,117 or any other process coming within the competence of a person skilled in the art who is an expert in chemical synthesis. For the chemical preparation of the products of the invention, a person skilled in the art is regarded as having at his disposal, inter alia, the entire contents of “Chemical Abstracts” and of the documents which are cited therein.
  • In addition to the patent discussing 1-N-arylpyrazoles derivatives discussed previously, one skilled in the art could make these compounds by adopting procedures described in DE 19928155, DE 19853560, WO 2000031043, DE 19650197, WO 9824769, U.S. Pat. No. 6265430, US 2001007876, all of which are herein incorporated by reference.
  • Insect growth regulating (IGR) compounds are another class of insecticides or acaricides, which are therapeutic agents that may be administered by the inventive applicator. Compounds belonging to this group are well known to the practitioner and represent a wide range of different chemical classes. These compounds all act by interfering with the development or growth of the insect pests. Compounds with an ovicidal and/or larvicidal effect on the immature stages of various ectoparasites are already known, for example from U.S. Pat. No. 5,439,924. Among these compounds described are those IGR compounds, which act either by blocking the development of the immature stages (eggs and larvae) into adult stages, or by inhibiting the synthesis of chitin. Insect growth regulators are described, for example, in U.S. Pat. No. 3,748,356; U.S. Pat. No. 3,818,047; U.S. Pat. No. 4,225,598; U.S. Pat. No. 4,798,837; and U.S. Pat. No. 4,751,225, as well as in EP 179,022 or U.K. 2,140,010. French Patent No. A-2,713,889 generally describes an IGR combination comprising at least one compound with juvenile hormone activity and chitin synthesis inhibitors, with at least one of three N-arylpyrazole compounds, in particular fipronil or thiofipronil, to control many harmful insects belonging to very varied orders.
  • Examples of IGR compounds which may be used in this invention include compounds which mimic juvenile hormones, in particular:
      • azadirchtin-Agridyne
      • diofenolan (Ciba Geigy now Novartis)
      • fenoxycarb (Ciba Geigy now Novartis)
      • hydroprene (Sandoz now Novartis)
      • kinoprene (Sandoz now Novartis)
      • methoprene (Sandoz now Novartis)
      • pyriproxyfen (Sumitomo/Mgk)
      • tetrahydroazadirachtin (Agridyne)
      • 4-chloro-2-(2-chloro-2-methylpropyl)-5-(6-iodo-3-pyridylmethoxy)pyridizin-3(2H)-one
      • and chitin-synthesis inhibitors, in particular:
      • chlorfluazuron (Ishihara Sangyo)
      • cyromazine (Ciba Geigy now Novartis)
      • diflubenzuron (Solvay Duphar)
      • fluazuron (Ciba Geigy now Novartis)
      • flucycloxuron (Solvay Duphar)
      • flufenoxuron (Cyanamid)
      • hexaflumuron (Dow Elanco)
      • lufenuron (Ciba Geigy now Novartis)
      • tebufenozide (Rohm & Haas)
      • teflubenzuron (Cyanamid)
      • triflumuron (Bayer).
  • These compounds are defined by their international common name (The Pesticide Manual, 10th edition, 1994, Ed. Clive Tomlin, Great Britain).
  • Chitin-synthesis inhibitors also include compounds such as 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-((trifluoromethyl))phenylurea, 1 -(2,6-difluorobenzoyl)-3-(2-fluoro-4-(1,1,2,2-tetrafluoroethoxy))phenylurea and 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-trifluoro-methyl)phenylurea. Novaluron (Isagro, Italian company) is also an example of an IGR compound.
  • Preferred IGR compounds include methoprenes, pyriproxyfens, hydroprene, cyromazine, lufenuron, 1-(2,6-difluorobenzoyl)-3-(2-fluoro-4-(trifluoromethyl)phenylurea and novaluron.
  • Estrogens, progestins, and androgens refers to classes of chemical compounds which are also well known to a practitioner in this art. In fact, estrogens and progestins are among the most widely prescribed drugs and are used, for example, alone or in combination for contraception or hormone replacement therapy in post menopausal women. Estrogens and progestins occur naturally or are prepared synthetically. This class of compounds also includes estrogens or progesterone receptor antagonists. Antiestrogens, such as tamoxifen and clomiphene, are used to treat breast cancer and infertility. Antiprogestives are used as contraceptives and anticancer drugs, as well as to induce labor or terminate a pregnancy.
  • The androgens and antiandrogens structurally related to the estrogens and progestins as they are also biosynthesized from cholesterol. These compounds are based on testosterone. Androgens are used for hypogonadism and promote muscle development. Antiandrogens are used, for example, in the management of hyperplasia and carcinoma of the prostate, acne, and male pattern baldness as well as in the inhibition of the sex drive in men who are sex offenders. Estrogen, progestins, and androgens are described, for example, in “Goodman & Gilman's The Pharmacological Basis of Therapeutics,” 9th ed., J. G. Handman and L. Elimbird, eds., Ch. 57 to 60, pp. 1411-1485, McGraw Hill, New York (1996) or in “Principles of Medicinal Chemistry,” 2nd ed., W. O. Foye, ed., Ch. 21, pp. 495-559, Lea & Febiger, Philadelphia (1981).
  • Estrogens, progestins and androgens are also used in animal husbandry as growth promoters for food animals. It is known in the art that compounds of these classes act as growth-promoting steroids in animals such as cattle, sheep, pigs, fowl, rabbits, etc. Delivery systems to promote the growth of animals are described, for example, in U.S. Pat. No. 5,401,507, U.S. Pat. No. 5,288,469, U.S. Pat. No. 4,758,435, U.S. Pat. No. 4,686,092, U.S. Pat. No. 5,072,716 and U.S. Pat. No. 5,419,910.
  • NSAIDs are well known in the art. The classes of compounds which belong to this group include salicylic acid derivatives, para-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids (fenamates), enolic acids, and alkanones. NSAIDs exert their activity by interfering with prostaglandin biosynthesis by irreversibly or reversibly inhibiting cycloxygenase. Also included are COX-2 inhibitors which act by inhibiting the COX-2 receptor. Compounds of this group possess analgesic, antipyretic and nonsteroidal anti-inflammatory properties. Compounds belonging to these classes are described, for example, in Chapter 27 of Goodman and Gilman on pages 617 to 658 or in Ch. 22 of Foye on pages 561 to 590 as well as in U.S. Pat. No. 3,896,145; U.S. Pat. No. 3,337,570; U.S. Pat. No. 3,904,682; U.S. Pat. No. 4,009,197; U.S. Pat. No. 4,223,299; and U.S. Pat. No. 2,562,830, as well as the specific agents listed in The Merck Index. Especially preferred COX-2 inhibitors include 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one or 3-(cyclopropylethoxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl)-5H-furan-2-one, including the polymorphic B form of this compound, and the pharmaceutically acceptable salts or hydrates of these compounds. Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one is characterized by the following parameters
    cristalline system Trigonal
    space group R-3
    Description hexagonal
    unit-cell dimensions
    a (Å) 18.183
    b (Å) 18.183
    c (Å) 26.950
    α (°) 90
    β (°) 90
    γ (°) 120
    unit-cell volume (Å3) 7716.5
    number of molecules per unit-cell Z 18
    Temperature of measurement (° K) 293
    calculated specific gravity 1.303
    weight absorption coefficient (cm−1) 2.11
  • and further characterized by the following X-ray diffraction data calculated from crystalline structure:
    d(Angs) Intensity
    13,596 w
    10,238 w
    9,092 s
    8,983 m
    7,558 vw
    6,798 vw
    6,39 m
    6,39 vw
    6,194 vw
    5,812 m
    5,812 w
    5,444 w
    5,444 vw
    5,249 s
    5,119 s
    5,1 vw
    4,546 vw
    4,532 s
    4,532 s
    4,492 m
    4,461 m
    4,448 w
    4,311 vw
    4,311 vw
    4,155 s
    4,155 m
    4,056 vw
    4,056 vw
    4,027 vw
    4,027 vw
    3,995 m
    3,995 w
    3,895 w
    3,74 vw
    3,665 vw
    3,665 vw
    3,581 m
    3,489 vw
    3,489 vw
    3,459 vw
    3,436 vw
    3,436 vw
    3,413 w
    3,413 vw
    3,399 vw
    3,393 m
    3,393 vw
    3,233 vw
    3,209 w
    3,209 vw
    3,195 w
    3,195 vw
    3,184 m
    3,184 vw
    3,179 vw
    3,128 vw
    3,067 vw
    3,031 vw
    3,001 vw
    3,001 vw
    2,994 vw
    2,958 vw
    2,958 vw
    2,932 vw
    2,906 vw
    2,906 vw
    2,888 vw
    2,853 vw
    2,844 vw
    2,813 vw
    2,768 vw
    2,753 vw
    2,729 vw
    2,729 vw
    2,722 vw
    2,722 vw
    2,719 vw
    2,667 w
    2,667 vw
    2,634 vw
    2,624 vw
    2,608 vw
    2,522 vw
    2,519 vw
    2,519 vw
    2,512 vw
    2,504 vw
    2,504 vw
    2,501 vw
    2,464 vw
    2,464 vw
    2,455 vw
    2,438 vw
    2,428 vw
    2,428 vw
    2,417 vw
    2,364 vw
    2,339 vw
    2,301 vw
  • Macrolides are a class of antibiotics which contain a many-membered lactone ring to which are attached one or more deoxy sugars. Macrolides are generally bacteriostatic, but have been shown to be bacteriocidal in high concentration against very susceptible organisms. Macrolides are most effective against gram-position cocci and bacilli, although they do possess some activity against some gram-negative organism. Macrolides exert their bacteriostatic activity by inhibiting bacterial protein synthesis by binding reversibly to the 50 S ribosomal subunit. (“Goodman & Gillman's the Pharmacological Basis of Therapeutics,” 9th ed., J. G. Hadman & L. E. Limbird, eds., ch. 47, pp. 1135-1140, McGraw-Hill, New York (1996)).
  • The macrolides as a class are colorless and usually crystalline. The compounds are generally stable in near neutral solution, but they only have limited stability in acid or base solutions. The reason for this is because the glycosidic bonds hydrolyze in acid and the lactone ring saponifies in base (“Principles of Medicinal Chemistry,” 2nd ed., W. F. Foye, ed., ch. 31, pp. 782-785, Lea & Febiger, Philadelphia (1981)).
  • The macrolide anthelmintic compounds contemplated for use in the present invention are also well known to a practitioner of this art. These compounds include avermectins and milbemycins discussed above. Non-limiting examples of compounds belonging to this class are represented by the following structure:
    Figure US20060011666A1-20060119-C00014
    where the broken line indicates a single or a double bond at the 22,23-positions;
      • R1 is hydrogen or hydroxy provided that R1 is present only when the broken line indicates a single bond;
      • R2 is alkyl of from 1 to 6 carbon atoms or alkenyl of from 3 to 6 carbon atoms or cycloalkyl of from 3 to 8 carbon atoms;
      • R3 is hydroxy, methoxy or ═NOR5 where R5 is hydrogen or lower alkyl; and
      • R4 is hydrogen, hydroxy or
        Figure US20060011666A1-20060119-C00015
        where R6 is hydroxy, amino, mono-or di-lower alkylamino or lower alkanoylamino.
  • Additional compounds are avermectin Bla/Blb (abamectin), 22,23-dihydro avermectin Bla/Blb (ivermectin) and the 4″-acetylamino-5-ketoximino derivative of avermectin Bla/Blb. Both abamectin and ivermectin are approved as broad-spectrum antiparasitic agents. The 4″-acetyl amino-5-ketoximino derivatives of avermectin Bla/Blb has the following structural formula:
    Figure US20060011666A1-20060119-C00016
    where R2 is isopropyl or sec-butyl.
  • The avermectin products are generally prepared as a mixture of at least 80% of the compound where R2 is sec-butyl and no more than 20% of the compound where R2 is isopropyl. Other known avermectins include ememectin, eprinomectin and doramectin. Preferred milbemycin compounds which may be used as therapeutic agents include milbemycin αi and moxidectin.
  • The monosaccharide avermectin derivatives are also useful in combination with the present invention, especially where an oxime substitution is present on the 5-position of the lactone ring. Such compounds are described, for example, in EP 667,054. Also contemplated are all pharmaceutical and veterinary acceptable acid or base salt forms of these compounds as well as the corresponding ester and amide derivatives of these compounds, where applicable. Specific compounds which belong to this class of macrolide antiparasitic agents are well known to the practitioner of this art.
  • The bioactive agent in the present invention can be a macrolide, as macrolides are soluble in many organic solvents but are only slightly water soluble.
  • Macrolides as a class include the erythromycin and its derivatives as well as other derivatives such as the azalides. Erythromycin (MW 733.94 daltons) is the common name for a macrolide antibiotic produced by the growth of a strain of Streptomyces erythreous. It is a mixture of three erythromycins, A, B and C consisting largely of erythromycin A. Its chemical name is (3R*,4S*,5S*,6R*,7R*,9R*, 11R*,12R* ,13S*,14R*)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexapyranosyl]oxy]oxacyclotetradecane-2,10-dione, (C37H67NO13).
  • Erythromycin has a broad and essentially bacteriostatic action against many Gram-positive and some Gram-negative bacteria as well as other organisms including mycoplasmas, spirochetes, chlamydiae and rickettsiae. In humans, it finds usefulness in the treatment of a wide variety of infections. It finds wide application in veterinary practice in the treatment of infectious diseases such as pneumonias, mastitis, metritis, rhinitis, and bronchitis in cattle, swine and sheep.
  • Other derivatives of erythromycins include carbomycin, clarithromycin, josamycin, leucomycins, midecamycins, mikamycin, miokamycin, oleandomycin, pristinamycin, rokitamycin, rosaramicin, roxithromycin, spiramycin, tylosin, troleandomycin, and virginiamycin. As with the erythromycins, many of these derivatives exist as component mixtures. For example, carbomycin is a mixture of carbomycin A and carbomycin B. Leucomycin exists as a mixture of components A1, A2, A3, A9, B1-B4, U and V in various proportions. Component A3 is also known as josamycin and leucomycin V is also known as miokomycin. The major components of the midecamycins is midecamycin A and the minor components are midecamycins A2, A3 and A4. Likewise, mikamycin is a mixture of several components, mikamycin A and B. Mikamycin A is also known as virginiamycin M1. Pristinamycin is composed of pristinamycins IA, IB, and IC, which are identical to virginiamycins B2, B13 and B2 respectively, and pristinamycin IIA and IIB, which are identical to virginiamycin M1 and 26,27-dihydrovirginiamycin M1. Spiramycin consists of three components, spiromycin I, II, and III. Virginiamycin is composed of virginiamycin S1 and virginiamycin M1. All these components may be used in this invention. Sources of these macrolides are well known to the practitioner and are described in the literature in references such as “The Merck Index,” 12th ed., S. Budarari, ed., Merck & Co., Inc., Whitehouse Station, N.J. (1996).
  • The azalides are semisynthetic macrolide antibiotics related to erythromycin A and exhibit similar solubility characteristics. The structure of azithromycin is known. Useful azalide compounds are disclosed in EP 508699, herein incorporated by reference. The corresponding basic and acid addition salts and ester derivatives of the macrolides compounds are also contemplated for use in this invention. These salts are formed from the corresponding organic or inorganic acids or bases. These derivatives include the customary hydrochloride and phosphate salts as well as the acetate, propionate and butyrate esters. These derivatives may have different names. For example, the phosphate salt of oleandomycin is matromycin and the triacetyl derivative is troleandomycin. Rokitamycin is leucomycin V 4-B-butanoate, 3B-propionate.
  • Combinations of one or more of the therapeutic agents described above are contemplated. For example the therapeutic agents nodulisporamide derivatives or 1-N-arylpyrazoles may be combined with other insecticides, parasiticides, and acaricides. Such combinations include anthelminitic agents, such as those discussed above which include ivermectin, avermectin, and emamectin, as well as other agents such as thiabendazole, praziquantel, febantel or morantel. Alternatively, other combinations may include imidicloprid or a COX-2 inhibitor.
  • Non-limiting examples of topical formulations that are preferred include those comprising:
      • a) a pharmaceutically active combination consisting of at least one macrocyclic lactone and at least one compound selected from the group consisting of praziquantel, morantel and pyrantel;
      • b) optionally, a thickening agent;
      • c) a non-aqueous solvent; and
      • d) optionally, an antioxidant, a colorant, an acidifying stabilizer, an opacifier, a preservative and a crystallization inhibitor, wherein the pharmaceutically active combination is disclosed in the non-aqueous solvent.
        These formulations may be of the spot-on or pour-on type.
  • Other preferred spot-on and pour-on compositions include formulations comprising:
  • (A) 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulfinylpyrazole; or
  • (B) 1-N-phenylpyrazole derivative of the formula:
    Figure US20060011666A1-20060119-C00017
  • Other preferred spot-on or pour-on formulations are those comprising, for example, comprising from 0.05 to 25% weight/volume, relative to the total solution, of a compound of the formula:
    Figure US20060011666A1-20060119-C00018
    wherein:
      • R1 represents H2N—CS—;
      • R2 represents S(O)nR, 4,5-dicyanoimidazol-2-yl or haloalkyl;
      • R3 represents alkyl, haloalkyl, haloalkenyl or haloalkynyl;
      • R4 represents hydrogen, halogen, alkyl, haloalkyl, amino or a compound selected from the group consisting of
        Figure US20060011666A1-20060119-C00019
        wherein
      • R5 represents alkyl, halogenoalkyl, alkoxyalkyl or in each case unsubstituted or substituted phenyl or pyridyl,
      • R6 represents hydrogen or alkyl,
      • R7 represents hydrogen, alkyl or in each case unsubstituted or substituted phenyl or pyridyl,
      • R8 represents alkyl, alkenyl, alkynyl, formyl, alkylcarbonyl, halogenoalkylcarbonyl, or alkoxycarbonyl,
      • or a radical NR9R9R10, S(O)mR11, C(O)R11, C(O)R11, OR12, or —N═C(R13)(R14)
      • wherein
      • R9 and R10 independently represent a hydrogen atom or an alkyl, haloalkyl, C(O)alkyl, alkyoxycarbonyl or a S(O)rCF3 radical; or R9 and R10 may together form a divalent alkenyl radical which may be interrupted by one or two heteroatoms;
      • R11 represent an alkyl or haloalkyl radical;
      • R12 represents an alkyl or haloalkyl radical or a hydrogen atom;
      • R13 represents an alkyl radical or a hydrogen atom;
      • R14 represents a phenyl or a heteroaryl group optionally substituted with one or more halogen atoms or OH, —O-alkyl, S-alkyl, cyano or alkyl;
      • m, n q, r represents independently of each other an integer equal to 0, 1, or 2;
      • Ar represents unsubstituted or substituted phenyl or pyridyl, and n represents a number 0, 1 or 2,
        wherein the composition comprises from 0.05 to 25% weight/volume of the compound of formula (II), and the compound of formula (II) is applied in a dose between 0.1 and 2 mg/kg animal weight.
  • Especially, preferred are those, for example, which contain Frontline®, Frontline plus®, or Revolution®, as described in U.S. Pat. Nos. 6,426,333; 6,482,425; 6,395,765; 6,096,329; and 6,685,954.
  • Other especially preferred spot-on or pour-on formulations include: synergistic spot-on compositions for the long lasting protection against ectoparasites on mammals which comprises synergistic amounts
      • (A) at least one compound of the formula:
        Figure US20060011666A1-20060119-C00020
        in which:
      • R1 is CN or methyl or a halogen atom;
      • R2 is S(O)nR3 or 4,5-dicyanoimidazol-2-yl or haloalkyl;
      • R3 is alkyl or haloalkyl;
      • R4 represents a hydrogen or halogen atom; or a radical NR5 R6, S(O)mR7, C(O)R7, C(O)O—R7, alkyl, haloalkyl, or OR8 or a radical —N═C(R9)(R10);
      • R5 and R6 independently represent a hydrogen atom or an alkyl, haloalkyl, C(O)alkyl, alkoxycarbonyl or S(O)r—CF3 radical; R5 and R6 may together form a divalent alkylene radical which may be interrupted by one or two divalent hereto atoms or;
      • R7 represents an alkyl or haloalkyl radical;
      • R8 represents an alkyl or haloalkyl radical or a hydrogen atom;
      • R9 represents an alkyl radical or a hydrogen atom;
      • R10 represents a phenyl or heteroaryl group optionally substituted with one or more halogen atoms or one or more substituents selected from the group consisting of OH, —O-alkyl, S-alkyl, cyano or alkyl;
      • R11 and R12 represent, independently of each other, hydrogen, halogen, CN or NO2;
      • R13 represents a halogen atom or a haloalkyl, haloalkoxy, S(O)qCF3 or SF5 group;
      • m, n, q and r represent, independently of each other, an integer equal to 0, 1 or 2;
      • X represents a trivalent nitrogen atom or a radical C—R12, the other three valency positions of the carbon atom forming part of the aromatic ring;
      • with the proviso that when R1 is methyl, then R3 is haloalkyl, R4 is NH2, R11 is Cl, R13 is CF3 and X is N; or R2 is 4,5-dicyanoimidazol-2-yl, R4 is Cl, R11, is Cl, R13 is CF3 and X is ═C—Cl;
  • (B) at least one insect growth regulator (IGR) that mimics juvinile hormones;
  • (C) imidacloprid; and
  • a fluid vehicle comprising at least one customary spot-on formulation adjuvant; or a composition comprising
  • (A) an effective amount of at least one compound of the formula
    Figure US20060011666A1-20060119-C00021
    in which:
      • R1 is a halogen atom, CN or methyl;
  • R2 is S(O)nR3 or 4,5-dicyanoimidazol-2-yl or haloalkyl;
      • R3 is alkyl or haloalkyl;
      • R4 represents a hydrogen or halogen atom or an NR5R6, (S)O)mR7, C(O)R7, alkyl, haloalkyl or O8 radical or an —N═C(R9)(R10) radical;
      • R5 and R6 independently represent a hydrogen atom or an alkyl, haloalkyl, C(O)alkyl, S(O)rCF3 or alkoxycarbonyl radical or R5 and R6 can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;
      • R7 represents an alkyl or a haloalkyl radical;
      • R8 represents an alkyl or haloalkyl radical or a hydrogen atom;
      • R9 represents an alkyl radical or a hydrogen atom;
      • R10 represents an optionally substituted aryl or an optionally substituted heteroaryl group;
      • R11 and R12 represent, independently of one another, hydrogen , halogen CN or NO2;
      • R13 represents a halogen atom or a haloalkyl, haloalkoxy, S(O)qCF3 or SF5 group;
      • m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2;
      • X represents a trivalent nitrogen atom or a C—R12 radical, the three other valencies of the carbon atom forming part of the aromatic ring;
      • with the proviso that, when R1 is mehyl, then R3 is haloalkyl, R4 is Cl, R13 is CF3 and X is N or else R2 is 4,5-dicyanoimidazol-2-yl, R4 is Cl, R11 is Cl, R13 is CF3 and X is C—Cl; and/or
  • (B) a pharmaceutical or veterinary effective amount of a macrocyclic lactone antihelmintic or antiparasitic agent;
  • (2) a pharmaceutically or veterinary acceptable liquid carrier vehicle; and
  • (3) optionally, a crystallization inhibitor,
  • with spot-on compositions comprising
  • (A) 1-[2,6-Cl2-4-CF3 phenyl]-3-CN-4-[SO—CF3]-5-NH2 pyrazole; and
  • (B) ivermectin and milbemectin; or
  • where the composition comprises
  • (A) 1-[2,6-Cl2-4-CF3 phenyl]-3-CN-4-[SO—CF3]-5-NH2pyrazole; and
  • (B) selamectin,
  • being especially p referred. Other preferred macrocyclic lactones include a vermectins, abamectin, doramectin, moxidectin, and milbemycin.
  • Frontline® is a spot-on product comprises fipronil, ethanol, polvidone, Tween 80, butylhydroxytoluene, butlyhydroxyanisole and diethylene glycol monomethylether. Frontline Plus® contains the same ingredients as Frontline® except that it further includes (S)-methoprene. Revolution® is a spot-on product comprising selamectin in isopropanol, polyvidone, Tween 80, butylhydroxytoluene, dipropylene glycol monomethylether.
  • The topical formulations used in the present invention may include other formulations adjuvants well know to a practitioner in this art. Non-limiting examples of these additives are as follows:
  • The thickeners are well known to a practitioner of this art and may be added to these formulations. Compounds which function as thickeners include, for example, povidone, maltodextrin, polydextrate, EMDEX (dextrates), carboxypolymethylene (Carbomer®), polyethylene glycol and celluloses, such as hydroxypropyl celluloses. An especially preferred thickener is povidone. Thickeners may be present in amounts of from about 0.1% to about 25%.
  • Opacifiers may be added to absorb and/or reflect certain light and/or energy of certain wavelengths and may thus enhance the stability of the formulations. Opacifiers include, for example, zinc oxide or titanium dioxide and may be present in amounts from about 0.5 to 2.5%. Titanium dioxide is especially preferred. These compounds are well known to practitioners of this art.
  • Additionally, the formulations may contain other inert ingredients such as antioxidants, preservatives, or pH stabilizers. These compounds are well known in the formulation art. Antioxidant such as an alpha tocopheral, ascorbic acid, ascrobyl palmitate, fumeric acid, malic acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), monothioglycerol and the like, may be added to the present formulation. The antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0%, based upon total weight of the formulation, with about 0.05 to about 1.0% being especially preferred. Preservatives, such as the parabens (methylparaben and/or propylparaben), are suitably used in the formulation in amounts ranging from about 0.01 to about 2.0%, with about 0.05 to about 1.0% being especially preferred. Other preservatives include benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and the like. Preferred ranges for these compounds include from about 0.01 to about 5%.
  • Colorants may be added to the formulations. Specific colorants include, for example, dyes, an aluminum lake, caramel, colorant based upon iron oxide or a mixture of any of the foregoing. Especially useful are organic dyes and titanium dioxide. Preferred ranges include from about 0.1% to about 25%.
  • Solvents for the formulations would be readily known in the art and include, for example, glycerol formal, 1-methylpyrrolidone (NMP), propylene, glycol, polyethylene glycol, benzyl alcohol, mixtures of glyceride/triglyceride and their derivatives, such as caprilic/capric acid triglyceride, or fatty acid esters (miglyol products) diethylene glycol monoethyl ether (transcutol®), lauroglycol 90, dimethylfomamide (DMF), dimethyl sulfoxide (DMSO) and mixtures of these solvents.
  • Administration of the inventive formulation may be intermittent in time and may be administered daily, weekly, biweekly, monthly, bimonthly, quarterly, or even for longer durations of time. The time period between treatments depends upon factors such as the parasite(s) being treated, the degree of infestation, the type of mammal or bird and the environment where it resides. It is well within the skill level of the practitioner to determine a specific administration period for a particular situation.
  • Spot-on and pour-on formulations may be prepared by dissolving the therapeutic agents into the pharmaceutically or veterinary acceptable vehicle. Alternatively, the spot-on formulation can be prepared by encapsulation of the active ingredient to leave a residue of the therapeutic agent on the surface of the animal. These formulations will vary with regard to the weight of the therapeutic agent in the combination depending on the therapeutic agent, the species of host animal to be treated, the severity and type of infection and the body weight of the host. The compounds may be administered continuously, particularly for prophylaxis, by known methods. Generally, a dose of from about 0.001 to about 10 mg per kg of body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but, of course, there can be instance where higher or lower dosage ranges are indicated and such are within the scope of this invention. It is well within the routine skill of the practitioner to determine a particular dosing regimen for a specific therapeutic agent for a specific host and parasite.
  • Preferably, a single formulation containing for example, a 1-N-arylpyrazole derivative in a substantially liquid carrier and in a form which makes possible a single application, or an application repeated a small number of times, will be administered to the animal over a highly localized region of the animal, preferably between the two shoulders. Most preferably, this localized region has a surface area of less than 10 cm, especially between 5 and 10 cm2 area.
  • It also may be preferable to use controlled-release formulations.
  • It is understood that the dosage values which are thus indicated are average values which may vary within a wide range. For example, a formulation having defined doses of 1-N-arylpyrazole-type derivative and of an IGR compound will be administered to animals having relatively different weights. Consequently, the doses actually applied are often smaller or larger by a factor which may be up to 2, 3 or 4 relative to the preferred dose, without entailing any toxic risk for the animal in the case of an overdose, and while at the same time retaining real efficacy, possibly of shorter duration, in the case of an underdose.
  • The spot-on formulations that are used in present invention provide for the topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to a spot on the animal, generally between the two shoulders (solution of spot-on type). It has been discovered that the inventive formulations are especially active against parasites when the formulations are applied to mammals and birds, especially poultry, dogs, cats, sheep, pigs, cattle zebras, horses, donkeys, mice, chipmunks and tree squirrels.
  • Also contemplated are the pharmaceutically or veterinary-acceptable acid or base salts, where applicable, of the therapeutic agents provided for herein. The term “acid” contemplates all pharmaceutically or veterinary acceptable inorganic or organic acids. Inorganic acids include mineral acids such as hydrohalic acids, such as hydrobromic and hydrochloric acids, sulfuric acids, phosphoric acids and nitric acids. Organic acids include all pharmaceutically or veterinary-acceptable aliphatic, alicyclic and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids and fatty acids. Preferred acids are straight chain or branched, saturated or unsaturated C1-C20 aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C6-C12 aromatic carboxylic acids. Examples of such acids are carbonic acid, formic acid, fumaric acid, acetic acid, propionic acid, isopropionic acid, valeric acid, α-hydroxy acids, such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane sulfonic acid, and salicylic acid. Examples of dicarboxylic acids include oxalic acid, malic acid, succinic acid, tataric acid and maleic acid. An example of a tricarboxylic acid is citric acid. Fatty acids include all pharmaceutically or veterinary-acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms. Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylsteric acid. Other acids include gluconic acid, glycoheptonic acid and lactobionic acid.
  • The term “base” contemplates all pharmaceutically or veterinary acceptable inorganic or organic bases. Such bases include, for example, the alkali metal and alkaline earth metal salts, such as the lithium, sodium, potassium, magnesium or calcium salts. Organic bases include the common hydrocarbyl and heterocyclic amine salts, which include, for example, the morpholine and piperidine salts.
  • The organic solvent for the liquid carrier vehicle will preferably have a dielectric constant of between about 10 and about 35, preferably between about 20 and about 30, the content of this solvent in the overall composition preferably representing the remainder of 100% of the composition. It is well within the skill level of the practitioner to select a suitable solvent on the basis of these parameters.
  • The organic cosolvent for the liquid carrier vehicle will preferably have a boiling point of less than about 100° C., preferably of less than about 80° C., and will have a dielectric constant of between about 10 and about 40, preferably between about 20 and about 30; this cosolvent can advantageously be present in the composition according to a weight/weight (W/W) ratio with respect to the solvent of between about 1/15 and about 1/2; the cosolvent is volatile in order to act in particular as drying promoter and is miscible with water and/or with the solvent. Again, it is well within the skill level of the practitioner to select a suitable solvent on the basis of these parameters.
  • The organic solvent for the liquid carrier includes the commonly acceptable organic solvents known in the formulation art. These solvents may be found, for example, in Remington Pharmaceutical Science, 16th Edition (1986). These solvents include, for example, acetone, ethyl acetate, methanol, ethanol, isopropanol, dimethylformamide, dichloromethane or diethylene glycol monoethyl ether (Transcutol). These solvents can be supplemented by various excipients according to the nature of the desired phases, such as C8-C10 caprylic/capric triglyceride a hydrogenated or fractionated coconut oil (Estasan or Miglyol 812), oleic acid or propylene glycol.
  • The liquid carrier may also comprise a microemulsion. Microemulsions are also well suited as the liquid carrier vehicle. Microemulsions are quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids.
  • Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase. The size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions). The interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously.
  • The oily phase can in particular be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such compounds. The oily phase preferably comprises triglycerides and more preferably medium-chain triglycerides, for example C8-C10 caprylic/capric triglyceride. The oily phase will represent, in particular, from about 2 to about 15% more, particularly from about 7 to about 10%, preferably from about 8 to about 9%, V/V of the microemulsion. Suitable oils for the oily phase are known in the art and are described, for example, in U.S. Pat. No. 6,036,394; U.S. Pat. No. 5,580,574; U.S. Pat. No. 6,174,540 and WO 97/37653, herein incorporated by reference.
  • The aqueous phase includes, for example, water or glycol derivatives, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol. Propylene glycol, diethylene glycol monoethyl ether and dipropylene glycol monoethyl ether are especially preferred. Generally, the aqueous phase will represent a proportion from about 1 to about 4% V/V in the microemulsion.
  • Surfactants for the microemulsion include diethylene glycol monoethyl ether, dipropylene glycol monomethyl ether, polyglycolysed C8-C10 glycerides or polyglyceryl-6 dioleate. In addition to these surfactants, the cosurfactants include short-chain alcohols, such as ethanol and propanol.
  • Some compounds are common to the three components discussed above, i.e., aqueous phase, surfactant and cosurfactant. However, it is well within the skill level of the practitioner to use different compounds for each component of the same formulation.
  • The cosurfactant to surfactant ratio will preferably be from about 1/7 to about 1/2. There will preferably be from about 25 to about 75% V/V of surfactant and from about 10 to about 55% V/V of cosurfactant in the microemulsion.
  • Likewise, the co-solvents are also well known to a practitioner in the formulation art. Preferred co-solvents are those which are promoters of drying and include, for example, absolute ethanol, isopropanol (2-propanol) or methanol.
  • The crystallization inhibitor can in particular be present in a proportion of about 1 to about 20% (W/V), preferably of about 5 to about 15%. The inhibitor preferably corresponds to the test in which 0.3 ml of a solution comprising 10% (W/V) of the compound of formula (I) in the liquid carrier and 10% of the inhibitor are deposited on a glass slide at 20° C. and allowed to stand for 24 hours. The slide is then observed with the naked eye. Acceptable inhibitors are those whose addition provides for few or no crystals, and in particular less than 10 crystals, preferably 0 crystals.
  • Optionally, the formulation can optionally comprise water, in particular in a proportion of 0 to about 30% (volume by volume V/V), in particular of 0 to about 5%, although this is not always preferred.
  • The formulation can also comprise an antioxidizing agent intended to inhibit oxidation in air, this agent being particularly present in a proportion of about 0.005 to about 1% (W/V), preferably of about 0.01 to about 0.05%.
  • Crystallization inhibitors which may be included in the spot-on or pour-on formulation. Non-limiting examples of crystallization inhibitors include:
      • polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates and others,
      • anionic surfactants, such as alkaline stearates, in particular sodium, potassium or ammonium stearate; calcium stearate or triethanolamine stearate; sodium abietate; alkyl sulphates, in particular sodium lauryl sulphate and sodium cetyl sulphate; sodium dodecylbenzenesulphonate or sodium dioctyl sulphosuccinate; or fatty acids, in particular those derived from coconut oil,
      • cationic surfactants, such as water-soluble quaternary ammonium salts of formula N+R′R″R′″R″″Y−, in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals and Y− is an anion of a strong acid, such as halide, sulphate and sulphonate anions; cetyltrimethylammonium bromide is one of the cationic surfactants which can be used,
      • amine salts of formula N+R40 R″R′″, in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals; octadecylamine hydrochloride is one of the cationic surfactants which can be used,
      • non-ionic surfactants, such as optionally polyoxyethylenated esters of sorbitan, in particular Polysorbate 80, or polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or copolymers of ethylene oxide and of propylene oxide,
      • amphoteric surfactants, such as substituted lauryl compounds of betaine,
      • or preferably a mixture of at least two of the compounds listed above.
  • In a particular preferred embodiment, a crystallization inhibitor pair will be used. Such pairs include, for example, the combination of a film-forming agent of polymeric type and of a surface-active agent. These agents will be selected in particular from the compounds mentioned above as crystallization inhibitors.
  • Particularly preferred film-forming agents of polymeric type include:
      • the various grades of polyvinylpyrrolidone,
      • polyvinyl alcohols, and
      • copolymers of vinyl acetate and of vinylpyrrolidone.
  • Especially preferred surface-active agents, include those made of non-ionic surfactants, preferably polyoxyethylenated esters of sorbitan and in particular the various grades of polysorbate, for example Polysorbate 80.
  • The film-forming agent and the surface-active agent can in particular be incorporated in similar or identical amounts within the limit of the total amounts of crystallization inhibitor mentioned elsewhere.
  • The pair thus constituted secures, in a noteworthy way, the objectives of absence of crystallization on the coat and of maintenance of the cosmetic appearance of the fur, that is to say without a tendency towards sticking or towards a sticky appearance, despite the high concentration of active material.
  • Particularly preferred antioxidizing agents are those conventional in the art and include, for example, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate, sodium thiosulphate or a mixture of not more than two of them.
  • The formulation adjuvants discussed above are well known to the practitioner in this art and may be obtained commercially or through known techniques. These concentrated compositions are generally prepared by simple mixing of the constituents as defined above; advantageously, the starting point is to mix the active material in the main solvent and then the other ingredients or adjuvants are added.
  • The determination of an effective amount of a given therapeutic agent would be well known to the practitioner since many the individual agents an combinations containing these agents are known. For example, the amount of 1-N-arylpyrazole for birds and animals which are small in size is preferably greater than about 0.01 mg and in a particularly preferred way between about 1 and about 50 mg/kg of weight of animal. For topical combinations comprising 1-N-arylpyrazoles and IGR's it is preferable to administer to the animal a dose of from about 0.1 to about 40 and in particular from about 1 to about 20 mg/kg of 1-N-phenylpyrazole and a dose of from about 0.1 to about 40 and in particular about 1 to about 30 mg/kg of IGR compound. Preferred doses are from about 5 to about 15 mg/kg of 1-N-arylpyrazoles and from about 0.5 to about 15 mg/kg for the preferred IGR compounds, or about 10 to about 20 mg/kg for the other IGR compounds.
  • For spot-on or pour-on formulations, the N-arylpyrazoles can advantageously be present in the formulations in a proportion of about 1 to about 20%, preferably of about 5 to about 15% (percentages as weight by volume=W/V). The liquid carrier vehicle comprises a pharmaceutically or veterinary acceptable organic solvent and optionally an organic cosolvent.
  • The volume applied can be of the order of about 0.3 to about 1 ml, preferably of the order of about 0.5 ml, for cats and of the order of about 0.3 to about 3 ml for dogs, depending on the weight of the animal.
  • For nodulisporic acid derivatives, generally a dose of from about 0.001 to about 100 mg per kg of body weight, with a range of 0.25 to 50 mg/kg being especially preferred, given as a single dose or in divided doses for a period of from about 1 to about 60 days, preferably from about 1 to 30 days.
  • Preferred amounts of anthelmintic agents such as praziquantel or morantel include, for example, from about 0.5 mg/kg to about 7.5 mg/kg of animal body weight, with a range of about 0.5 mg/kg to about 2 mg/kg or 2.5 mg/kg of body weight being especially preferred. A most especially preferred amount is about 1.0 mg/kg of animal body weight. Preferred ranges for the macrolide compounds include, for example about 0.01 to about 200 mg/kg of animal body weight, with the ranges of about 0.1 to about 50 mg/kg and from about 1 to about 30 mg/kg being especially preferred.
  • Having thus described in detail preferred embodiments of the present invention, it is to be understood that the invention defined by the appended claims is not to be limited to particular details set forth in the above description as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.

Claims (13)

1. A liquid agent applicator comprising:
a collapsible reservoir for storing the liquid agent;
a shaft having a lumen there through connected to said collapsible reservoir;
an opening mechanism inserted into an orifice formed in one end of said shaft; and
a breakable seal formed between said opening mechanism and said shaft, wherein twisting of said opening mechanism relative to said shaft breaks said seal allowing egress of the liquid agent stored in said reservoir.
2. The liquid applicator of claim 1, wherein said seal is formed by thermoforming.
3. The liquid applicator of claim 1, wherein said seal is formed between the opening mechanism and an interior surface of said shaft.
4. The liquid applicator of claim 1, wherein said seal is formed by matching threads formed on said opening mechanism and said shaft.
5. The liquid applicator of claim 1, wherein said seal is formed by the elastic properties of said shaft conforming to the shape of said opening mechanism inserted therein.
6. The liquid applicator of claim 1, further comprising grips formed on said reservoir.
7. The liquid applicator of claim 1, further comprising a flat base.
8. The liquid applicator of claim 1, wherein said reservoir is formed by thermoforming one or more sheets of plastic material.
9. The liquid applicator of claim 1, formed of a chemically compatible material for use with anti-flea and tick agents.
10. The liquid applicator of claim 1, wherein said opening mechanism is child resistant.
11. The liquid applicator of claim 10, wherein the child resistant opening mechanism comprises:
a rigid stationary neck;
a movable cap;
a septum for preventing the egress of liquid from said reservoir formed on said stationary neck;
a punch formed on said movable cap, for piercing said septum to allow the egress of liquid from said reservoir; and
an interlock requiring two or more movements of said movable cap by the user, wherein upon completion of said two or more actions, said movable cover is movable along said stationary neck in the direction of said septum, the movement of said movable cap causing said punch to pierce the septum.
12. The liquid agent applicator of claim 1 wherein the liquid agent is topical pharmaceutical or veterinary formulation.
13. The liquid agent applicator of claim 1, wherein the applicator is formed poly acrylo nitrile.
US10/892,261 2004-03-29 2004-07-15 Pipette/applicator Abandoned US20060011666A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/892,261 US20060011666A1 (en) 2004-07-15 2004-07-15 Pipette/applicator
MXPA04009556 MXPA04009556A (en) 2004-03-29 2004-09-29 Pipette/applicator and optional tops therefor.
EP05731101A EP1748930A4 (en) 2004-03-29 2005-03-28 Pipette/applicator
PCT/US2005/010446 WO2005094330A2 (en) 2004-03-29 2005-03-28 Pipette/applicator
AU2005201472A AU2005201472B2 (en) 2004-07-15 2005-04-07 Pipette/applicator and optional tops therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/892,261 US20060011666A1 (en) 2004-07-15 2004-07-15 Pipette/applicator

Publications (1)

Publication Number Publication Date
US20060011666A1 true US20060011666A1 (en) 2006-01-19

Family

ID=35598399

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/892,261 Abandoned US20060011666A1 (en) 2004-03-29 2004-07-15 Pipette/applicator

Country Status (2)

Country Link
US (1) US20060011666A1 (en)
AU (1) AU2005201472B2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080245314A1 (en) * 2007-04-05 2008-10-09 Brodowski Thomas Fluid delivery assembly
US20080245380A1 (en) * 2007-04-05 2008-10-09 Ecker William Fluid applicator
US20090105672A1 (en) * 2007-10-17 2009-04-23 Cascio Gregory R Medicament applicator
US20090105673A1 (en) * 2007-10-17 2009-04-23 Cascio Gregory R Medicament applicator
US20130292414A1 (en) * 2012-05-02 2013-11-07 Spencer D. Sutherland Dispensing Device
US20140228785A1 (en) * 2008-11-19 2014-08-14 Merial Limited Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
USD726900S1 (en) 2011-04-12 2015-04-14 Sergeant's Pet Care Products, Inc. Device for storing and dispensing a medicament
US20150126898A1 (en) * 2012-08-30 2015-05-07 Mystic Pharmaceuticals, Inc. Fully Self-Contained Unit Dose Devices for Allergy Skin Testing
US10179678B2 (en) 2017-04-26 2019-01-15 The Hartz Mountain Corporation Applicator with breakaway cap
US10532836B2 (en) * 2016-02-29 2020-01-14 Klocke Verpackungs-Service Gmbh Method for the productions and filling of an application package for a liquid pharmaceutical product
WO2020217287A1 (en) * 2019-04-22 2020-10-29 株式会社大阪製薬 Insect pest-controlling tool for animals
US11000681B2 (en) * 2014-09-29 2021-05-11 Icb Pharma Spolka Jawna Applicator for external action formulations, in particular a disposable applicator for formulations combatting ectoparasites
US11377263B2 (en) * 2017-11-09 2022-07-05 3M Innovative Properties Company Dispenser with applicator tip
US11426568B2 (en) * 2018-01-26 2022-08-30 The Procter & Gamble Company Applicators for treating vaginal dryness

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512475A (en) * 1983-11-04 1985-04-23 Alberto Federighi Single or multiple dose container-closure assemblies
US4566613A (en) * 1982-08-03 1986-01-28 Schering-Prebbles Limited Multiple opening structure receptacle
US5018646A (en) * 1988-11-23 1991-05-28 S. C. Johnson & Son, Inc. Squeezable fluid container
US5301849A (en) * 1989-05-17 1994-04-12 Rical S.A. Spout assembly and sealing cap with spring-loaded hinge
US5577636A (en) * 1994-06-10 1996-11-26 Yoshida Kogyo Co., Ltd. Multi-tube container having breakable connections at both ends thereof
US5735426A (en) * 1996-12-17 1998-04-07 Alcoa Closure Systems International Inc. Fitment-closure assembly for gable-topped carton
US6234333B1 (en) * 1996-06-27 2001-05-22 Lameplast S.R.L. Reclosable container
US6260735B1 (en) * 2000-05-12 2001-07-17 Colgate-Palmolive Company Uniform dispensing dual chamber sachet
US6991140B2 (en) * 2003-06-02 2006-01-31 E.I. Du Pont De Nemours And Company, Inc. Fitment for a flexible pouch with child-safety properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3858739A (en) * 1973-03-05 1975-01-07 Barnes Hind Diagnostics Inc Breakaway neck container with integral cap

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4566613A (en) * 1982-08-03 1986-01-28 Schering-Prebbles Limited Multiple opening structure receptacle
US4512475A (en) * 1983-11-04 1985-04-23 Alberto Federighi Single or multiple dose container-closure assemblies
US5018646A (en) * 1988-11-23 1991-05-28 S. C. Johnson & Son, Inc. Squeezable fluid container
US5301849A (en) * 1989-05-17 1994-04-12 Rical S.A. Spout assembly and sealing cap with spring-loaded hinge
US5577636A (en) * 1994-06-10 1996-11-26 Yoshida Kogyo Co., Ltd. Multi-tube container having breakable connections at both ends thereof
US6234333B1 (en) * 1996-06-27 2001-05-22 Lameplast S.R.L. Reclosable container
US5735426A (en) * 1996-12-17 1998-04-07 Alcoa Closure Systems International Inc. Fitment-closure assembly for gable-topped carton
US6260735B1 (en) * 2000-05-12 2001-07-17 Colgate-Palmolive Company Uniform dispensing dual chamber sachet
US6991140B2 (en) * 2003-06-02 2006-01-31 E.I. Du Pont De Nemours And Company, Inc. Fitment for a flexible pouch with child-safety properties

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8668400B2 (en) 2007-04-05 2014-03-11 The Hartz Mountain Corporation Fluid applicator
US20080245380A1 (en) * 2007-04-05 2008-10-09 Ecker William Fluid applicator
WO2008124408A1 (en) * 2007-04-05 2008-10-16 The Hartz Mountain Corporation Fluid applicator
US8109236B2 (en) 2007-04-05 2012-02-07 Sumitomo Corporation Of America Fluid delivery assembly
RU2473397C2 (en) * 2007-04-05 2013-01-27 Дзе Хартц Маунтин Корпорейшн Fluid applicator
US20080245314A1 (en) * 2007-04-05 2008-10-09 Brodowski Thomas Fluid delivery assembly
US20090105672A1 (en) * 2007-10-17 2009-04-23 Cascio Gregory R Medicament applicator
US20090105673A1 (en) * 2007-10-17 2009-04-23 Cascio Gregory R Medicament applicator
US7806878B2 (en) * 2007-10-17 2010-10-05 Cascio Gregory R Medicament applicator
US20140228785A1 (en) * 2008-11-19 2014-08-14 Merial Limited Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
US9173728B2 (en) * 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
USD726900S1 (en) 2011-04-12 2015-04-14 Sergeant's Pet Care Products, Inc. Device for storing and dispensing a medicament
USD728094S1 (en) 2011-04-12 2015-04-28 Sergeant's Pet Care Products, Inc. Device for storing and dispensing a medicament
US20130292414A1 (en) * 2012-05-02 2013-11-07 Spencer D. Sutherland Dispensing Device
US20150126898A1 (en) * 2012-08-30 2015-05-07 Mystic Pharmaceuticals, Inc. Fully Self-Contained Unit Dose Devices for Allergy Skin Testing
US9445762B2 (en) * 2012-08-30 2016-09-20 Mystic Pharmaceuticals, Inc. Fully self-contained unit dose devices for allergy skin testing
US11000681B2 (en) * 2014-09-29 2021-05-11 Icb Pharma Spolka Jawna Applicator for external action formulations, in particular a disposable applicator for formulations combatting ectoparasites
US10532836B2 (en) * 2016-02-29 2020-01-14 Klocke Verpackungs-Service Gmbh Method for the productions and filling of an application package for a liquid pharmaceutical product
US10179678B2 (en) 2017-04-26 2019-01-15 The Hartz Mountain Corporation Applicator with breakaway cap
US11377263B2 (en) * 2017-11-09 2022-07-05 3M Innovative Properties Company Dispenser with applicator tip
US11426568B2 (en) * 2018-01-26 2022-08-30 The Procter & Gamble Company Applicators for treating vaginal dryness
WO2020217287A1 (en) * 2019-04-22 2020-10-29 株式会社大阪製薬 Insect pest-controlling tool for animals

Also Published As

Publication number Publication date
AU2005201472B2 (en) 2010-05-13
AU2005201472A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
AU2005201472B2 (en) Pipette/applicator and optional tops therefor
CN102271672B (en) Compositions comprising 1-arylpyrazoles, alone or in combination with formamidines, for the treatment of parasitic infections
TWI707679B (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US8242161B2 (en) Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
JP2020203891A (en) Parasiticidal compositions comprising isoxazoline active agent, and methods and uses thereof
AU2006276997B2 (en) Spot-on formulations for combating parasites
US20030166688A1 (en) Spot-on formulations for combating parasites
US20080003282A1 (en) Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
NO329469B1 (en) Long acting injectable formulations containing hydrogenated castor oil
MX2012011360A (en) Parasiticidal compositions comprising multiple active agents, methods and uses thereof.
US20050234119A1 (en) Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
WO2005094330A2 (en) Pipette/applicator
EP1748930A2 (en) Pipette/applicator
MXPA04009556A (en) Pipette/applicator and optional tops therefor.
HK1116007A (en) Spot-on formulations for combating parasites
MXPA00005552A (en) Long acting injectable formulations containing hydrogenated castor oil

Legal Events

Date Code Title Description
AS Assignment

Owner name: MERIAL LIMITED, GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WURTZ, PATRICE;LEIBENGUTH, SUSAN;REEL/FRAME:016312/0524

Effective date: 20040707

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION